

CURRICULUM VITAE

Date updated: March 26, 2018

Name: Jason L. Hornick, M.D., Ph.D.

Office Address: Department of Pathology
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115

Home Address: 99 Fairfield Street
Needham, MA 02492

Work Phone: (617) 525-7257

Work E-mail: jhornick@bwh.harvard.edu

Work FAX: (617) 566-3897

Place of Birth: Los Angeles, CA

Education

1991	B.A. (<i>cum laude</i>)	Russian and Biology	Amherst College
1997	Ph.D.	Pathobiology Advisor: Alan L. Epstein, M.D., Ph.D.	University of Southern California
1999	M.D.	Medicine	University of Southern California

Postdoctoral Training

1999-2003	Clinical Fellow	Pathology	Harvard Medical School
1999-2001	Resident	Anatomic Pathology	Brigham and Women's Hospital
2001 (July-Sept.)	Fellow	Gynecologic Pathology	Brigham and Women's Hospital
2001 (Oct.-Dec.)	Chief Resident	Anatomic Pathology	Brigham and Women's Hospital
2002 (Jan.-Mar.)	Fellow	Soft Tissue Pathology	Brigham and Women's Hospital
2002 (Apr.-June)	Fellow	Hematopathology	Brigham and Women's Hospital
2002-2003	Fellow	Gastrointestinal Pathology	Brigham and Women's Hospital

Academic Appointments

2003-2005	Instructor	Pathology	Harvard Medical School
2005-2009	Assistant Professor	Pathology	Harvard Medical School
2009-2017	Associate Professor	Pathology	Harvard Medical School
2017-present	Professor	Pathology	Harvard Medical School

Jason L. Hornick, M.D., Ph.D.

Appointments at Hospitals/Affiliated Institutions

2003-2009	Associate Pathologist	Pathology	Brigham and Women's Hospital
2009-present	Pathologist	Pathology	Brigham and Women's Hospital
2005-present	Consultant	Pathology	Dana-Farber Cancer Institute
2005-2009	Consultant	Pathology	Children's Hospital Boston

Major Administrative Leadership Positions

2007-present	Director, Immunohistochemistry Laboratory, Department of Pathology, Brigham and Women's Hospital
2009-2013	Associate Director of Surgical Pathology, Brigham and Women's Hospital
2009-present	Co-Director, Surgical Pathology Update Course, Brigham and Women's Hospital
2013-present	Director of Surgical Pathology, Brigham and Women's Hospital

Local Committee Service

2003-present	Resident Recruitment and Selection Committee, Department of Pathology, Brigham and Women's Hospital
2009-present	Chair, Surgical Pathology Quality Assurance Committee, Department of Pathology, Brigham and Women's Hospital
2009-present	Education Committee, Department of Pathology, Brigham and Women's Hospital
2009-present	Executive Committee, Brigham and Women's Hospital Mastocytosis Center
2012-2013	Standing Committee on Continuing Education, Harvard Medical School
2013-present	Clinical Operations Committee, Department of Pathology, Brigham and Women's Hospital
2013-present	Steering Committee, Center for Esophageal and Gastric Cancer, Dana Farber/Brigham and Women's Cancer Center
2013-present	Center for Cancer Precision Medicine, Dana Farber Cancer Institute
2014-present	Steering Committee, Pancreaticobiliary Tumor Center, Dana Farber/Brigham and Women's Cancer Center
2014-present	Co-Chair, Tissue Committee, Brigham and Women's Hospital

Jason L. Hornick, M.D., Ph.D.

- 2016-present Cancer Committee, Dana Farber/Brigham and Women's Cancer Center
- 2016-present Steering Committee, Profile project, Dana Farber/Brigham and Women's Cancer Center

National Committee Service

- 2014-2017 Soft Tissue Sarcoma Expert Panel member, American Joint Committee on Cancer Staging System
- 2014-2017 Sarcoma Analysis Working Group member, The Cancer Genome Atlas (TCGA)
- 2015-present Test Development and Advisory Committee for Anatomic Pathology, American Board of Pathology

International Committee Service

- 2012 W.H.O. Classification of Tumors of Soft Tissue and Bone, 4th edition, Consensus and Editorial Working Group member
- 2012 Consensus Meeting on Classification and Diagnostic Criteria for Mastocytosis, Working Group member
- 2018 W.H.O. Classification of Tumors of Soft Tissue and Bone, 5th edition, Editorial Board expert member

Professional Societies:

- 2000-present College of American Pathologists
- 2009-2017 Member, Immunohistochemistry Committee
- 2011-2012 Vice Chair, Immunohistochemistry Committee
- 2013-2017 Chair, Immunohistochemistry Committee
- 2000-present United States and Canadian Academy of Pathology
- 2009 Abstract Review Committee (Gastrointestinal Pathology)
- 2010, 2011 Moderator, Bone and Soft Tissue Pathology platform sessions
- 2010-present Member, Education Committee
- 2012-2017 Chair, Abstract Review Board and Abstract Assignment Committee
- 2013, 2014 Moderator, Gastrointestinal Pathology platform session
- 2015-2017 Moderator, Bone and Soft Tissue Pathology specialty conference
- 2017-2020 Chair, Education Committee
- 2017-2020 Director, Interactive Microscopy Soft Tissue Pathology course
- 2018-2020 Co-Director, Diagnostic Pathology Update course
- 2000-present American Society for Clinical Pathologists
- 2002-present American Gastroenterological Association
- 2002-present American College of Gastroenterology
- 2004-present New England Society of Pathologists

Jason L. Hornick, M.D., Ph.D.

2004-present	International Society of Bone & Soft Tissue Pathology
2015-present	Officer At-Large
2005-present	Gastrointestinal Pathology Society
2009-present	Arthur Purdy Stout Society of Surgical Pathologists
2011-2016	Co-Chair, Program Committee
2011-present	Member, Council
2017-present	Chair, Membership Committee
2010-present	Association of Directors of Anatomic and Surgical Pathology (ADASP)
2014-present	Member, Council
2016-present	Pancreatobiliary Pathology Society
2016-present	Histiocyte Society

Editorial Activities

- ***Ad hoc* Reviewer**

Acta Pathologica Microbiologica et Immunologica Scandinavica	Head and Neck Pathology
Acta Neuropathologica	Histology and Histopathology
American Journal of Dermatopathology	Inflammatory Bowel Diseases
American Journal of Hematology	International Journal of Infectious Diseases
American Journal of Gastroenterology	International Journal of Pediatric Otorhinolaryngology
American Journal of Pathology	Journal of Allergy and Clinical Immunology
Archives of Dermatology	Journal of Cellular and Molecular Medicine
Archives of Pathology and Laboratory Medicine	Journal of Clinical Pathology
Blood	Journal of Cutaneous Pathology
BMC Gastroenterology	Journal of Molecular Diagnostics
BMC Oncology	Journal of Pathology
BMC Surgery	Journal of the European Academy of Dermatology and Venereology
Brain	Laboratory Investigation
British Journal of Dermatology	Lancet Oncology
Cancer	The Oncologist
Cancer Genetics	Pathology
Clinical Cancer Research	Pathology Research International
Dermatology	Pathology Research and Practice
Diagnostic Cytopathology	PLoS One
Endocrine	Transplant Infectious Disease
Future Oncology	World Journal of Gastroenterology
Gastrointestinal Endoscopy	World Journal of Gastrointestinal Oncology
Genes Chromosomes Cancer	World Journal of Gastrointestinal Surgery
Head & Neck	

- **Editorial Roles**

2007-present	Editorial Board	American Journal of Clinical Pathology
2008-present	Editorial Board	Applied Immunohistochemistry & Molecular Morphology
2008	Guest Editor	Diagnostic Histopathology, Symposium on Soft Tissue Tumors

Jason L. Hornick, M.D., Ph.D.

2009-present	Editorial Board	American Journal of Surgical Pathology
2010-present	Editorial Board	Human Pathology
2010-present	Associate Editor	Advances in Anatomic Pathology
2012-present	Regional Editor (North America)	Histopathology
2012-present	Section Editor (Surgical Pathology)	<i>Pathobiology of Human Disease</i> (Elsevier)
2012-present	Associate Editor	<i>Sternberg's Diagnostic Surgical Pathology</i> (Lippincott)
2013	Guest Editor	Surgical Pathology Clinics (Gastrointestinal Pathology issue)
2013-present	Associate Editor, Endocrine Pathology	Histopathology
2013-present	Editorial Board	International Journal of Surgical Pathology
2013-present	Editorial Board	Seminars in Diagnostic Pathology
2014-present	Associate Editor, Soft Tissue Pathology	Histopathology
2014	Guest Editor	Histopathology (Annual Review Issue: Soft Tissue Tumors)
2014-2015	Guest Editor	Seminars in Diagnostic Pathology (Immunohistochemistry)
2014-present	Editorial Board	Modern Pathology
2015-present	Consulting Editor	Surgical Pathology Clinics
2016-2017	Guest Editor	Histopathology (Annual Review Issue: Surgical Pathology of 21 st Century Medicine)
2016-present	Executive Advisory Board	Archives of Pathology and Laboratory Medicine
2016-present	Editorial Board	Virchows Archiv: The European Journal of Pathology
2016-present	Associate Editor	American Registry of Pathology (formerly Armed Forces Institute of Pathology) Atlases

Honors and Prizes

1990	Research Fellowship, American Heart Association
1995-1996	Charles Heidelberger Memorial Scholarship, University of Southern California/ Norris Comprehensive Cancer Center, Cancer Research
1997	Louis B. Silverman Memorial Award, Health Physics Society, Cancer Research
1997	Clinical Research Scholar Award, American Association for Cancer Research- Glaxo Wellcome Oncology
1997-1999	Dean's Scholar, University of Southern California School of Medicine
1999	Phi Kappa Phi All-University Honor Society, University of Southern California
2007	Pier F. Paci Memorial Award for Excellence in Teaching, Brigham and Women's Hospital, Department of Pathology
2012	Arthur Purdy Stout Society of Surgical Pathologists Annual Prize, in recognition of significant career achievements in surgical pathology under the age of 45 years
2014	Gastrointestinal Pathology Society Jack Yardley Investigator Award, in recognition of seminal contributions that advance the field of GI pathology

Report of Funded and Unfunded Projects

Past Unfunded Projects

2005-2012	PI	Biomarkers in pancreatic and gastrointestinal neuroendocrine tumors I studied the diagnostic and predictive value of novel biomarkers for well- differentiated neuroendocrine tumors of the pancreas and gastrointestinal tract.
-----------	----	---

- 2010-2012 PI HER2/neu and ER in gastroesophageal adenocarcinomas
I compared the sensitivity of traditional rabbit polyclonal and mouse monoclonal antibodies to novel rabbit monoclonal antibodies in gastric and esophageal adenocarcinomas.
- 2012-2014 PI BRAF V600E immunohistochemistry
I evaluated the specificity of a monoclonal antibody for V600E-mutant BRAF in various tumor types.

Current Unfunded Projects

- 2003-present PI Clinicopathologic study of soft tissue tumors
I am characterizing the histologic and clinical features of soft tissue tumors in order to define clinical behavior and pathologic predictors of outcome.
- 2006-present PI Histiocytic and dendritic cell sarcomas
I am studying the clinical and pathologic features of histiocytic and dendritic cell sarcomas, evaluating pathologic predictors of outcome, and investigating the genetic alterations underlying their pathogenesis.
- 2010-present PI Novel diagnostic markers for sarcomas
I am evaluating the potential diagnostic utility of novel immunohistochemical markers for soft tissue tumors.
- 2011-present PI Mastocytosis and mast cell sarcoma
I am studying the clinical, histologic, and genomic features of cutaneous and systemic mastocytosis and mast cell sarcoma and evaluating novel diagnostic markers and potential prognostic indicators.
- 2012-present PI Succinate dehydrogenase-deficient tumors
I am investigating clinical and pathologic features and mechanisms of tumorigenesis in gastrointestinal stromal tumors and renal cell carcinomas characterized by succinate dehydrogenase inactivation.

Report of Local Teaching and Training

Teaching of Students in Courses

- 2001-2003 HMS PA501.23, Harvard Medical Student Clinical Clerkship in Pathology, Brigham and Women's Hospital
3rd- and 4th-year Medical Students Instructor 1-hr session monthly
- 2002-2009 HST-120, Gastrointestinal Pathophysiology, Harvard Medical School
1st-year Medical Students Laboratory Instructor 1-hr session weekly

Formal Teaching of Residents, Clinical Fellows and Research Fellows

2001-2003	Pathology/Oncology Conference Pathology and Oncology Fellows	BWH/DFCI	30-min lecture quarterly
2002-2003	Inflammatory Bowel Disease Working Conference Pathology, Gastroenterology Fellows	BWH	1-hr session bimonthly
2002-2003	Gastrointestinal Clinicopathologic Conference Pathology, Gastroenterology Fellows	BWH	1-hr session monthly
2003-present	Pancreatic Tumors Pathology Residents and Fellows	BWH	1-hr lecture
2003-present	Introduction to Immunohistochemistry Pathology Residents and Fellows	BWH	1-hr lecture
2003-2014	Non-epithelial Tumors of the Gastrointestinal Tract Pathology Residents and Fellows	BWH	1-hr lecture
2006	Pathology of Allergy and Immunology Allergy and Immunology Fellows	BWH	1-hr lecture
2008-present	Gastrointestinal Cancer Center Conference Oncology Fellows and Staff	DFCI	1-hr session bimonthly
2010-present	Quality Assurance and Surgical Pathology Reporting Pathology Residents and Fellows	BWH	1-hr lecture
2013-present	An Introduction to Oncologic Pathology Medical Oncology Fellows	DFCI	1-hr lecture
2015-present	Methods in Clinical Research: Biomarker Analysis Oncology Fellows	DFCI	1-hr lecture
2015	An Introduction to Oncologic Pathology Radiation Oncology Fellows	BWH	1-hr lecture
2015-present	Inflammatory Disorders of the Tubal Gut Pathology Residents and Fellows	BWH	1-hr lecture
2016-present	Spindle Cell Tumors of Soft Tissue Pathology Residents and Fellows	BWH	1-hr lecture
2016-present	Pleomorphic Soft Tissue Tumors Pathology Residents and Fellows	BWH	1-hr lecture

Jason L. Hornick, M.D., Ph.D.

Clinical Supervisory and Training Responsibilities

2003-2009	Hematopathology Resident/Fellow Preceptor	BWH	2-4 hrs/day; 8 wks/yr
2005-2009	Gastrointestinal Pathology Fellow Preceptor	CHB	1-2 hrs/day; 6 wks/yr
2003-present	Surgical Pathology, Gastrointestinal Pathology, and Soft Tissue Tumor Pathology Resident/Fellow Preceptor	BWH	1-4 hrs/day; 32 wks/yr

Formally Supervised Trainees and Faculty (All held Research Fellow or Clinical Fellow appointments at HMS)

2005-2006	Amitabh Srivastava, M.D. Published one manuscript	Associate Director of Surgical Pathology Brigham and Women's Hospital
2005-2006	Hongbo Yu, M.D., Ph.D. Published two manuscripts	Director of Hematology Laboratory UMass Medical School, Worcester, MA
2005-2007	Hejin P. Hahn, M.D., Ph.D. Published two manuscripts	Staff Pathologist Virginia Mason Hospital, Seattle, WA
2006-2007	Sandro Santagata, M.D., Ph.D. Published one manuscript	Staff Neuropathologist Brigham and Women's Hospital
2006-2007	Briana Gleason, M.D. Published two manuscripts	Staff Pathologist PathGroup, Nashville, TN
2007-2008	Travis J. Hollmann, M.D., Ph.D. Published two manuscripts	Staff Dermatopathologist Memorial Hospital, New York, NY
2007-2008	Joanna A. Gibson, M.D., Ph.D. Published one manuscript	Staff Pathologist Yale University, New Haven, CT
2007-2008	Derek K. Marsee, M.D., Ph.D. Published one manuscript	Staff Pathologist Diagnostic Pathology Medical Group, Sacramento, CA
2008-2010	Kevin B. Long, M.D. Published three manuscripts	Staff Pathologist Cellnetix, Olympia, WA
2008-2009	Lynette M. Sholl, M.D. Published two manuscripts	Chief, Pulmonary Pathology Service Brigham and Women's Hospital
2008-2009	Dominique Coco, M.D. Published one manuscript	Staff Pathologist Cellnetix, Olympia, WA

Jason L. Hornick, M.D., Ph.D.

2009-2010	Wai Chin (Tim) Foo, M.D. Published one manuscript	Assistant Professor M.D. Anderson Cancer Center, Houston, TX
2009-2011	Tanya Rege, M.D., Ph.D. Published one manuscript	Staff Pathologist Miraca Life Sciences, Newton, MA
2010-2011	Adrian Mariño-Enríquez, M.D. Published two manuscripts	Instructor in Pathology Brigham and Women's Hospital
2010-2011	Dick Hwang, M.D., Ph.D. Published one manuscript	Staff Pathologist Virginia Mason Hospital, Seattle, WA
2011-2012	Benjamin Chen, M.D., Ph.D. Published one manuscript	Staff Pathologist UMass Medical Center, Worcester, MA
2010-2012	Leona A. Doyle, M.D. Published three manuscripts	Staff Pathologist Brigham and Women's Hospital
2012-2013	Cheryl A. Adackapara, M.D. Published one manuscript	Staff Pathologist Mid-Atlantic Permanente Medical Group, Rockville, MD
2012-2015	Emily F. Mason, M.D., Ph.D. Published two manuscripts	Staff Hematopathologist Vanderbilt University, Nashville, TN
2012-2013	James R. Conner, M.D., Ph.D. Published one manuscript	Staff Pathologist Mount Sinai Hospital, Toronto, Canada
2013-2014	Marina Vivero, M.D. Published one manuscript	Staff Pathologist Brigham and Women's Hospital
2014-2015	Gabriel K. Griffin, M.D. Published one manuscript	Hematopathology Fellow Brigham and Women's Hospital
2015-2016	Inga-Marie Schaefer, M.D. Published three manuscripts	Pathology Resident Brigham and Women's Hospital
2015-2016	Yin P. Hung, M.D., Ph.D. Published four manuscripts	Pathology Resident Brigham and Women's Hospital
2016-2017	Juliana Andrici, M.B.B.S. Published one manuscript	Pathology Resident Brigham and Women's Hospital

Formal Teaching of Peers (e.g., CME and other continuing education courses)

2005-2010	Diagnosis and differential diagnosis of solid pancreatic tumors Gastrointestinal, Liver and Pancreatic Pathology	Single presentation Harvard Medical School
2006	Myoepithelial and nerve sheath tumors: An update Dermatopathology Update	Single presentation Harvard Medical School
2008	Gastrointestinal stromal tumors: An update Gastrointestinal, Liver and Pancreatic Pathology	Single presentation Harvard Medical School
2008-2010	Virtual slide seminar Gastrointestinal, Liver and Pancreatic Pathology	Single presentation Harvard Medical School
2008	Myoepithelial tumors and their mimics Bone and Soft Tissue Pathology for the Surgical Pathologist	Single presentation Harvard Medical School
2009-2013	GIST and other mesenchymal tumors of the GI tract Gastrointestinal, Liver and Pancreatic Pathology	Single presentation Harvard Medical School
2010	What do you need to know about pathology in IBD? Inflammatory Bowel Disease: The Art and Science in the Diagnosis and Treatment in 2010	Single presentation Boston University School of Medicine
2013, 2015	Pathology of colon polyps and cancer Comprehensive Review of Colon and Rectal Surgery	Single presentation Harvard Medical School
2014-present	Gastrointestinal stromal tumors: An update Gastrointestinal, Liver and Pancreatic Pathology	Single presentation Harvard Medical School
2015	Gastrointestinal stromal tumors: An update; Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry; An approach to cutaneous spindle cell tumors; An approach to spindle cell tumors of deep soft tissue; An approach to pleomorphic and epithelioid soft tissue tumors	Single presentation Surgical Pathology for the Practicing Pathologist Harvard Medical School
2015	Pathology of inflammatory bowel disease Board Review in Gastroenterology	Single presentation Harvard Medical School
2017	Colorectal polyps: A practical approach; Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry; The most common spindle cell tumors of soft tissue: Key features and differential diagnosis; Subclassification of pleomorphic sarcomas: How and why should we care?	Single presentation Surgical Pathology for the Practicing Pathologist Harvard Medical School

Jason L. Hornick, M.D., Ph.D.

- 2018 (scheduled) Mesenchymal tumors of the GI tract (other than GIST) Single presentation
Gastrointestinal, Liver and Pancreatic Pathology Harvard Medical School
- 2018 (scheduled) Beyond lineage: Diagnostic and predictive molecular immunohistochemistry
for surgical pathologists; Carcinoma of unknown primary: Diagnostic approach
using immunohistochemistry Single presentation
Current Concepts in Surgical Pathology Harvard Medical School

Local Invited Presentations

- 2004 Applications of immunohistochemistry for diagnostic surgical pathology / Invited
lecture
Department of Pathology, Children's Hospital Boston
- 2005 Immunohistochemistry in surgical pathology: An update / Invited lecture
Department of Pathology, Children's Hospital Boston
- 2006 Classification of nerve sheath tumors / Invited lecture
Department of Pathology, Children's Hospital Boston
- 2006 Surgical Pathology Update: Myoepithelial and nerve sheath tumors of soft tissue
and skin / Invited lecture
Department of Pathology, Brigham and Women's Hospital
- 2006 Gastrointestinal stromal tumors / Invited lecture
Department of Pathology, Children's Hospital Boston
- 2009 Mast Cell Activation Seminar: CD25 expression in mast cell activation syndromes:
A diagnostic marker of systemic mastocytosis at extramedullary sites / Invited lecture
Brigham and Women's Hospital
- 2010 Surgical Pathology Update: Mesenchymal tumors of the gastrointestinal tract / Invited
lecture
Department of Pathology, Brigham and Women's Hospital
- 2013 Gastrointestinal pathology: Biopsy diagnosis of inflammatory disorders / Invited
lecture
Division of Gastroenterology, Brigham and Women's Hospital
- 2013 Surgical Pathology Update: Succinate dehydrogenase deficiency and tumorigenesis /
Invited lecture
Department of Pathology, Brigham and Women's Hospital
- 2014 Center for Advanced Molecular Diagnostics Clinical Conference: Soft tissue
tumor pathology: an update on classification and molecular genetics including
"next generation" immunohistochemistry / Invited lecture
Department of Pathology, Brigham and Women's Hospital

Jason L. Hornick, M.D., Ph.D.

- 2014 Pathology of colon polyps and cancer / Invited lecture
Division of Gastroenterology, Brigham and Women's Hospital
- 2016 Gastrointestinal lymphomas: An update / Invited lecture
Division of Gastroenterology, Brigham and Women's Hospital
- 2016 The evolution of immunohistochemistry for soft tissue tumors: From
differentiation to molecular genetics / Grand rounds (Shields Warren Lecturer)
Department of Pathology, Beth Israel Deaconess Medical Center
- 2016 The evolution of immunohistochemistry for soft tissue tumors / Grand rounds
Department of Pathology, Massachusetts General Hospital
- 2017 Pathology of colorectal polyps and cancer: An update / Invited lecture
Division of Gastroenterology, Brigham and Women's Hospital
- 2017 21st century immunohistochemistry for soft tissue tumors / Invited lecture
Department of Pathology, Children's Hospital Boston
- 2017 Carcinoma of unknown primary: immunohistochemistry using lineage-restricted
transcription factors / Invited lecture
Gastrointestinal Cancer Center, Dana Farber Cancer Institute
- 2018 Gastrointestinal pathology: A luminal potpourri / Invited lecture
Division of Gastroenterology, Brigham and Women's Hospital

Report of Regional, National and International Invited Lectures and Presentations

Regional Invited Presentations and Courses

- 2004 Myoepithelioma of soft tissue / Case presentation
New England Society of Pathologists, Boston
- 2006 Annual Cancer Symposium: Advances in Approaches to the Treatment of Sarcomas:
Pathology of sarcomas / Invited lecture
Berkshire Medical Center, Pittsfield, MA
- 2006 Pathology of Barrett's esophagus / Invited lecture
Boston Surgical Society, Boston
- 2008 Soft tissue tumor pathology: New insights and novel markers / Grand rounds
Rhode Island Hospital, Providence, RI
- 2011 Recent advances in soft tissue tumor pathology / Grand rounds
Boston University Medical Center, Boston, MA

Jason L. Hornick, M.D., Ph.D.

- 2011 Bridge Project Symposium: Pathology of pancreatic cancer / Invited lecture
Koch Institute, Massachusetts Institute of Technology
- 2013 Advances in soft tissue tumor pathology: Immunohistochemistry and molecular
genetics / Grand rounds
University of Massachusetts, Worcester, MA
- 2014 A practical approach to the diagnosis of cutaneous spindle cell tumors / Invited lecture
Massachusetts Academy of Dermatology, Newport, RI
- 2015 Soft tissue tumor pathology: Recent advances in molecular genetics / Invited lecture
Hartford Hospital, Hartford, CT
- 2016 Innovations in Pathology Lecture: The evolution of diagnostic immunohistochemistry
for soft tissue tumors / Invited lecture
New England Society of Pathologists, Boston, MA
- 2017 Soft tissue tumors: A contemporary update / Invited lecture
Massachusetts Society of Pathologists, Waltham, MA
- 2018 (scheduled) What's new in soft tissue tumor pathology? / Grand rounds
University of Massachusetts, Worcester, MA

National Invited Presentations and Courses

- 2005 Tumors of the pancreas / Invited lecture
American Association of Pathologists' Assistants, Boston, MA
- 2006 Bone & Soft Tissue Pathology Specialty Conference: Myoepithelial carcinoma of soft
tissue / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Atlanta, GA
- 2008 Advances in soft tissue pathology: Recently described entities and improved
diagnostic tools / Invited lecture
Cellnetix, Seattle, WA
- 2009 Surgical Pathology Specialty Conference: PEComa / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Boston, MA
- 2009 Fibrohistiocytic lesions of children: An update; superficial nerve sheath tumors and
mimics / Invited lectures
American Society of Dermatopathology, Chicago, IL
- 2010 International Society of Bone and Soft Tissue Pathology Companion Meeting:
The prognostic role of immunohistochemistry in sarcomas / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Washington, DC

- 2010 Immunohistochemistry in soft tissue tumor pathology; mesenchymal tumors of the gastrointestinal tract / Invited lectures
Oklahoma State Association of Pathology, Oklahoma City, OK
- 2010 The molecular continuum of Barrett's esophagus to esophagogastric cancer / Invited lecture
American Society of Clinical Oncology, Chicago, IL
- 2010 Update on soft tissue tumor pathology: New molecular insights and novel diagnostic markers / 25th Rosalie O. Saffos Memorial Lecture
University of Florida, Jacksonville, FL
- 2010-2012 Non-melanocytic mimics of melanoma: Problems in differential diagnosis / Short course
United States and Canadian Academy of Pathology Annual Meeting
- 2010 Contemporary Topics in Surgical Pathology XXIV: Soft Tissue Pathology: Immunohistochemistry in soft tissue pathology; an update on cutaneous mesenchymal tumors; an update on nerve sheath tumors; an update on gastrointestinal mesenchymal tumors / Invited lectures
St. Thomas Hospital, Nashville, TN
- 2010 Recent advances in soft tissue tumors; diagnostic problems in surgical pathology / Invited lectures
California Society of Pathologists, San Francisco, CA
- 2011 Recent advances in soft tissue tumor pathology / Invited lectures
Arizona Society of Pathologists, Mesa, AZ
- 2011 Cutaneous mastocytosis and systemic mastocytosis: Diagnostic features and pathologic markers / Invited lecture
The Mastocytosis Society Conference, Boston, MA
- 2012-2014 Classification and prognostication of mesenchymal tumors of the gastrointestinal tract Short Course
United States and Canadian Academy of Pathology Annual Meeting
- 2012 Soft tissue tumor pathology: An update / Invited lectures
Florida Society of Pathology, West Palm Beach, FL
- 2012 Practical Pathology Seminars: Non-melanocytic mimics of melanoma: Problems in differential diagnosis / Short Course
United States and Canadian Academy of Pathology, Boston, MA

Jason L. Hornick, M.D., Ph.D.

- 2012 Foundations in Cancer Medicine Symposium: Order and Disorder in Development and Malignancy: Succinate dehydrogenase deficiency and human neoplasia / Invited lecture
Fox Chase Cancer Center, Philadelphia, PA
- 2012 Immunohistochemistry in soft tissue tumor pathology: Recent developments based on genetic alterations; gastrointestinal stromal tumors: from KIT to succinate dehydrogenase / Invited lectures
Seattle Area Quarterly Pathology Seminars, Phenopath, Seattle, WA
- 2012 Skin and gastrointestinal tract pathology / Invited lecture
Mastocytosis symposium and consensus meeting on classification and diagnostic criteria for mastocytosis, Boston, MA
- 2013 Update on soft tissue tumor pathology; Tumors of the pancreas: Immunohistochemistry in differential diagnosis; Practical approach to the diagnosis of cutaneous soft tissue tumors / Invited lectures
Applied Immunohistochemistry and Molecular Pathology Course, Miami, FL
- 2013 Gastrointestinal stromal tumors: From KIT to succinate dehydrogenase / Grand rounds
University of Pittsburgh, Pittsburgh, PA
- 2013 Gastrointestinal stromal tumors: An update / Grand rounds
Yale University, New Haven, CT
- 2013 Long course: Soft tissue pathology: Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Baltimore, MD
- 2013 Bone & Soft Tissue Pathology Specialty Conference: Succinate dehydrogenase-deficient gastrointestinal stromal tumors / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Baltimore, MD
- 2013 Cutaneous soft tissue tumors / Invited lectures
Dermpedia, Scottsdale, AZ
- 2013 New developments in soft tissue tumor pathology / Grand rounds
University of Iowa, Iowa City
- 2013 Surgical Pathology Update: Immunohistochemistry / Invited lecture
American Society of Clinical Pathology, Montreal, Canada
- 2013 Diagnostic Update: Soft tissue pathology and immunohistochemistry / Invited lectures
United States and Canadian Academy of Pathology, Anchorage, AK
- 2013 Surgical pathology update course: Soft tissue tumors / Invited lectures
Ohio State University, Columbus, OH

Jason L. Hornick, M.D., Ph.D.

- 2013 Gastrointestinal stromal tumors: From KIT to succinate dehydrogenase / Grand rounds
Vanderbilt University Medical Center, Nashville, TN
- 2014 Mesenchymal tumors of the gastrointestinal tract: An update / Invited lecture
New York Pathological Society, New York, NY
- 2014 Succinate dehydrogenase-deficient tumors: An update / Grand rounds
Cleveland Clinic, Cleveland, OH
- 2014 Gastrointestinal Pathology Society Companion Meeting: Metastatic carcinoma of
unknown primary: Diagnostic Approach Using Immunohistochemistry / Invited
lecture
United States and Canadian Academy of Pathology Annual Meeting, San Diego, CA
- 2014 Practical Pathology Seminars: Classification and prognostication of mesenchymal
tumors of the gastrointestinal tract / Short Course
United States and Canadian Academy of Pathology, New York, NY
- 2014 Surgical Pathology Update: Immunohistochemistry / Invited lecture
American Society of Clinical Pathology, Chicago, IL
- 2014 Succinate dehydrogenase-deficient tumors: Pathologic features, pathogenesis,
and clinical implications / Research seminar series
University of Virginia, Charlottesville, VA
- 2014 Soft tissue tumor pathology: An update on classification and molecular genetics
including “next generation” immunohistochemistry / Grand rounds
Case Western Reserve University, Cleveland, OH
- 2015 Interactive microscopy: Histologic variants of GIST and histologic mimics you
don’t want to miss! / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Boston, MA
- 2015-2017 A Pattern-Based Approach to the Diagnosis of Soft Tissue Tumors / Short Course
United States and Canadian Academy of Pathology Annual Meeting
- 2015 A practical approach to surgical pathology: Immunohistochemistry / Invited
lectures
Educational Symposia, Las Vegas, NV
- 2015 “Next generation” immunohistochemistry in soft tissue tumor pathology / Grand
rounds
UCLA, Los Angeles, CA
- 2015 Immunohistochemistry: Basics and Clinical Applications / Invited lectures
American Society of Clinical Pathology, Redondo Beach, CA

- 2015 Surgical pathology course: Soft tissue tumors / Invited lectures
Scientific Symposiums, Williamsburg, VA
- 2015 “Next generation” immunohistochemistry in the diagnosis of soft tissue tumors /
Grand rounds
Stanford University, Stanford, CA
- 2015 Surgical pathology course: Gastrointestinal pathology / Invited lectures
Scientific Symposiums, Hawaii
- 2015 Immunohistochemistry: Novel markers for soft tissue tumors / Grand Rounds
Geisinger Medical Center, Danville, PA
- 2016 Metastatic carcinoma of unknown origin: Diagnostic approach / Invited lecture
Texas Society of Pathologists, Dallas, TX
- 2016 Immunohistochemistry for soft tissue tumors: What's new? / Invited lecture
North Texas Society of Pathology, Dallas, TX
- 2016 An approach to the diagnosis of epithelioid and pleomorphic soft tissue tumors /
Grand rounds
UT Southwestern, Dallas, TX
- 2016 Gastrointestinal pathology and soft tissue tumor pathology / Invited lectures
Washington State Society of Pathologists Annual Meeting, Seattle, WA
- 2016 International Society of Bone and Soft Tissue Pathology Companion Meeting:
ALK fusion-positive mesenchymal tumors / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Seattle, WA
- 2016 Soft tissue tumor pathology and immunohistochemistry / Invited lectures
23rd Annual Seminar in Pathology, Pittsburgh, PA
- 2016 Immunohistochemistry: Basics and clinical applications / Invited lectures
American Society of Clinical Pathology, Chicago, IL
- 2016 Soft tissue tumors of the head and neck / Invited lecture
American Academy of Oral & Maxillofacial Pathology, Cincinnati, OH
- 2016 The evolution of immunohistochemistry for soft tissue tumors: From
differentiation to molecular genetics / Keynote speaker (A. James French Lecturer)
University of Michigan, Ann Arbor, MI
- 2016 Soft tissue tumor pathology: An anatomic and pattern-based approach / Interactive
microscopy course
United States and Canadian Academy of Pathology, Palm Springs, CA

- 2017 The evolution of immunohistochemistry for soft tissue tumors: From differentiation to molecular genetics / Grand rounds
University of Florida, Gainesville, FL
- 2017 Surgical pathology course: Soft tissue tumor pathology / Invited lectures
Scientific Symposiums, Hawaii
- 2017 Hot Topics: Immunohistochemistry in the evaluation of tumors of undetermined origin / Invited panel discussion
United States and Canadian Academy of Pathology Annual Meeting, San Antonio, TX
- 2017 Society of Hematopathology Companion Meeting: Classification, immunohistochemistry, and molecular genetics of dendritic cell neoplasms / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, San Antonio, TX
- 2017 The evolution of immunohistochemistry for soft tissue tumors: From differentiation to molecular genetics / Grand rounds
Memorial Sloan-Kettering Cancer Center, New York, NY
- 2017 Cutaneous soft tissue tumors / Invited lectures
Dermpedia, San Diego, CA
- 2017 Diagnostic immunohistochemistry: Novel markers for soft tissue tumors; approach to carcinoma of unknown primary / Keynote speaker
North Carolina Society of Pathologists, Wrightsville Beach, NC
- 2017 A practical review of soft tissue tumor and gastrointestinal pathology / Invited lectures
Educational Symposia, Alaska
- 2017 Surgical pathology update: Diagnostic pearls for the practicing pathologist: Immunohistochemistry / Invited lectures
Educational Symposia, Las Vegas, NV
- 2017 What's new in soft tissue tumor pathology? / Invited lecture
Madigan Army Medical Center, Tacoma, WA
- 2017 Diagnostic challenges in soft tissue tumor pathology / Invited lecture
Oregon Pathologists Association, Portland, OR
- 2017 Next generation immunohistochemistry for the diagnosis of soft tissue tumors / Grand rounds
Emory University, Atlanta, GA

Jason L. Hornick, M.D., Ph.D.

- 2017 Soft tissue tumor pathology: Novel diagnostic markers based on recent molecular insights; Diagnostic problems in surgical pathology / Invited lectures
California Society of Pathology, San Francisco, CA
- 2017 Diagnostic challenges in soft tissue and bone pathology: epithelioid tumors and round cell sarcomas / Interactive microscopy course
United States and Canadian Academy of Pathology, Palm Springs, CA
- 2018 High intensity interval training in GI pathology: GI lymphomas and other hematopoietic tumors: What do we need to know? GI mesenchymal tumors: from GIST to GNET / Interactive microscopy course
United States and Canadian Academy of Pathology, Palm Springs, CA
- 2018 The evolution of immunohistochemistry for soft tissue tumors in the 21st century: From differentiation to molecular genetics; Beyond lineage: Diagnostic and predictive molecular immunohistochemistry for surgical pathologists / Invited lectures
Applied Immunohistochemistry and Molecular Pathology Course, Key Largo, FL
- 2018 Rodger Haggitt Gastrointestinal Pathology Society: Beyond GIST: Recent advances in gastrointestinal mesenchymal tumors / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Vancouver
- 2018 Long course: The Limited Sample: Doing More with Less: Limited biopsies of soft tissue tumors: The contemporary role of immunohistochemistry and molecular diagnostics / Invited lecture
United States and Canadian Academy of Pathology Annual Meeting, Vancouver
- 2018 (scheduled) From KIT to succinate dehydrogenase: The GIST of it; Subclassification of pleomorphic sarcomas: How and why should we care? / Invited lectures
American Registry of Pathology Course, Johns Hopkins, Baltimore, MD
- 2018 (scheduled) The evolution of immunohistochemistry for soft tissue tumors: From differentiation to molecular genetics / Grand rounds
University of Minnesota, Minneapolis, MN
- 2018 (scheduled) Next generation immunohistochemistry for the diagnosis of soft tissue tumors / Grand rounds
University of Alabama, Birmingham, AL
- 2018 (scheduled) Modern surgical pathology through the expert eyes of APSS-USCAP: Soft tissue tumors of the extremities and trunk; Soft tissue tumors of the abdominal cavity, retroperitoneum, and visceral organs / Interactive microscopy course
United States and Canadian Academy of Pathology, Palm Springs, CA
- 2018 (scheduled) Recent advances in soft tissue pathology: Evolving classification, novel molecular findings, and new diagnostic markers / Interactive microscopy course
United States and Canadian Academy of Pathology, Palm Springs, CA

Jason L. Hornick, M.D., Ph.D.

2019-2021 (scheduled) Immunohistochemistry in Oncopathology: Indispensable Complement to a Morphology-Driven Pattern-Based Approach / Short Course
United States and Canadian Academy of Pathology Annual Meeting

2019 (scheduled) Current Issues in Anatomic Pathology: Soft tissue pathology / Invited lectures
UCSF, San Francisco, CA

2019 (scheduled): Geisinger Seminar in Anatomic Pathology: 21st century immunohistochemistry for soft tissue tumors / Invited lecture
Danville, PA

International Invited Presentations and Courses

2008 Intermediate grade malignancy in adipocytic tumors; gastrointestinal stromal tumors: mutational testing and tyrosine kinase inhibitor therapy / Invited lectures
Intercontinental Congress of Pathology, Barcelona, Spain

2008 An Integrated Approach to Soft Tissue Tumor Diagnosis: Inflammatory myofibroblastic tumors and related lesions; Benign Neoplasms and Pseudoneoplasms of Soft Tissue: Cellular neurothekeoma / Invited lectures
International Congress of the International Academy of Pathology, Athens, Greece

2009 Pathology of the PEComa family of tumors / Invited lecture
The LAM Foundation 2009 International Research Conference, Cincinnati, OH

2009 Soft tissue tumors of the gastrointestinal tract; atypical round cell inflammatory myofibroblastic tumors / Invited lectures
European Congress of Pathology, Florence, Italy

2009 Update on soft tissue tumor pathology: From morphology to molecular genetics and back again / Keynote address
Irish Society of Surgical Pathology, Cork, Ireland

2010 1st Edinburgh Dermatopathology Tutorial: Practical approach to the diagnosis of cutaneous soft tissue tumors / Invited lectures
The University of Edinburgh, Edinburgh, U.K.

2010 Pathology course: Gastrointestinal stromal tumor of the esophagus; Plenary Session: Surveillance: Reversal of Barrett's Esophagus: Is a clear distinction between prevalent and incident dysplasia mandatory to avoid bias in the study of surveillance cohorts? Plenary Session: Natural History of Barrett's Esophagus: May photodynamic therapy alter the natural history of dysplasia in Barrett's esophagus? / Invited lectures
OESO World Conference on Diseases of the Esophagus, Boston

Jason L. Hornick, M.D., Ph.D.

- 2010 Gastrointestinal stromal tumors - where do we stand with diagnosis, prognosis and genotyping? / Invited lecture
International Congress of the International Academy of Pathology, Sao Paulo, Brazil
- 2011 Update on immunohistochemistry in soft tissue pathology; update on gastrointestinal stromal tumors / Invited lectures
Maastricht, The Netherlands
- 2011 Novelties in dermatopathology: What's new in soft tissue tumors?
Soft tissue tumors at the border: Follicular dendritic cell sarcoma / Invited lectures
European Congress of Pathology, Helsinki, Finland
- 2012 Histopathological and immunohistochemical diagnosis of spindle cell sarcomas: Clues and pitfalls; atypical fibroxanthoma and its mimics; cutaneous mesenchymal and adnexal tumour pathology / Invited lectures
European Congress of Pathology, Prague, Czech Republic
- 2012 Vascular tumors of soft tissue: Diagnostic problems; update on immunohistochemistry in soft tissue tumors; Gynecologic pathology: Uterine PEComa; Bone and soft tissue pathology: Clear cell sarcoma-like tumor of the GI tract / Invited lectures
International Congress of the International Academy of Pathology, Cape Town
- 2013 Diagnostic Histopathology of Soft Tissue Tumors: Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors; Mesenchymal tumors of the GI tract: an update / Invited lectures
Treviso, Italy
- 2013 2nd Edinburgh Hematopathology Tutorial: Histiocytic and dendritic cell tumors / Invited lectures
The University of Edinburgh, Edinburgh, U.K.
- 2013 Soft tissue tumor pathology: Low grade fibromyxoid sarcoma; targeted therapies in sarcomas: What pathologists need to know and report; Soft tissue tumor pathology: How I diagnose cellular fibrous histiocytoma vs atypical fibrous histiocytoma vs atypical fibroxanthoma vs pleomorphic dermal sarcoma; Surgical pathology: How I diagnose deep soft tissue spindle cell neoplasms / Invited lectures
XXIX Brazilian Congress of Pathology, Florianopolis, Brazil
- 2013 An update on soft tissue tumor pathology / Invited lectures
Tan Tock Seng Hospital, Singapore
- 2014 21st Update in Dermatopathology: What's new in cutaneous soft tissue tumours? / Invited lecture
London, U.K.

Jason L. Hornick, M.D., Ph.D.

- 2014 Spindle cell tumors of deep soft tissue: Differential diagnosis and novel markers; Gastrointestinal stromal tumors: An update / Invited lectures
Western University, London, Ontario, Canada
- 2014 Molecular pathology of skin malignancies: Cutaneous mesenchymal tumors; Challenges in immunohistochemistry and genetics of soft tissue tumors; Important diagnoses in dermatopathology / Invited lectures
European Congress of Pathology, London, U.K.
- 2014 An update on soft tissue tumor pathology / Invited lectures
Perth, Australia
- 2015 Diagnostic surgical pathology course: Gastrointestinal and soft tissue tumor pathology / Invited lectures
South Africa
- 2015 Diagnostic histopathology of soft tissue tumors: Challenges in immunohistochemistry and genetics of soft tissue tumors; Differential diagnosis of epithelioid soft tissue tumors / Invited lectures
Treviso, Italy
- 2015 Practical challenges in sarcoma diagnostics: Epithelioid soft tissue tumors; Update on cutaneous mesenchymal tumors: Pseudomyogenic hemangioendothelioma
Invited lectures
European Congress of Pathology, Belgrade, Serbia
- 2015 An update on applications of immunohistochemistry in diagnostic surgical pathology / Invited lectures
Timisoara, Romania
- 2015 An update on gastrointestinal pathology / Invited lectures
Nagaoka, Japan
- 2016 A tour around bone and soft tissue tumors / Invited lectures
Barcelona, Spain
- 2016 William Anderson Day lecture: The evolution of immunohistochemistry for soft tissue tumors: From differentiation to molecular genetics / Invited lecture
University of Toronto, Toronto, Canada
- 2016 Rodger Haggitt Gastrointestinal Pathology Society: Mesenchymal lesions of the gastrointestinal tract / Invited lecture
Joint International Congress of the International Academy of Pathology and European Congress of Pathology, Cologne, Germany

Jason L. Hornick, M.D., Ph.D.

- 2016 Evolving classification of soft tissue tumors / Keynote speaker
6th National Annual Conference on Soft Tissue and Bone Tumor Pathology,
Shanghai, China
- 2017 The evolution of immunohistochemistry for soft tissue tumors: From
differentiation to molecular genetics; Metastatic carcinoma of unknown primary:
approach to diagnosis using lineage-restricted transcription factor
immunohistochemistry (thank you, developmental biology) / Keynote speaker
Australasian Division of the International Academy of Pathology, Sydney, Australia
- 2017 The evolution of immunohistochemistry for soft tissue tumors: From
differentiation to molecular genetics / Invited lecture
50th Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic
Association, Tokyo, Japan
- 2017 Kyushu-Okinawa Conference: Mesenchymal tumors of the gastrointestinal tract:
An Update / Invited lecture
Fukuoka, Japan
- 2017 Spindle cell tumors of deep soft tissue: Key features and differential diagnosis /
Invited Lecture
Kyoto, Japan
- 2017 Diagnostic histopathology of soft tissue tumors / Invited lectures
Treviso, Italy
- 2018 Current Topics from the Next Generation of AFIP/ARP Fascicles: Spindle cell
tumors of the upper gastrointestinal tract: the GIST of it and more / Invited lecture
Morphologietage Bamberg, Bamberg, Germany
- 2018 (scheduled) An update on soft tissue tumor pathology, gastrointestinal pathology, and
diagnostic immunohistochemistry / Invited lectures
Educational Symposia, Mediterranean and Aegean
- 2018 (scheduled) Diagnostic Pathology Update: Spindle cell tumors of deep soft tissue: What do
we need to know? An approach to epithelioid soft tissue tumors: It's getting easier!
Mesenchymal tumors of the GI tract; Subclassification of pleomorphic sarcomas:
How and why should we care? / Invited lectures
United States and Canadian Academy of Pathology, Florence, Italy
- 2018 (scheduled) Cutaneous soft tissue tumor pathology / Invited lectures
Copenhagen, Denmark
- 2019 (scheduled) Recent Advances in Oncologic Pathology: Mesenchymal tumors of the
gastrointestinal tract / Invited lectures
Padua, Italy

Jason L. Hornick, M.D., Ph.D.

2019 (scheduled) 10th Edinburgh Dermatopathology Tutorial: Approach to cutaneous soft tissue tumors / Invited lectures
The University of Edinburgh, Edinburgh, U.K.

2019 (scheduled) Bone and soft tissue tumor pathology symposium / Invited lectures
St. Petersburg, Russia

2020 (scheduled) From the soft tissue through the bone to the bone marrow / Invited lectures
Warsaw, Poland

Report of Clinical Activities and Innovations

Current Licensure and Certification

2001- Commonwealth of Massachusetts Full Medical License
2002 American Board of Pathology (Anatomic Pathology)

Practice Activities

Surgical Pathology	Hospital practice	Pathology, BWH	12 weeks per year
Soft Tissue Tumor Pathology (Institutional consults)	Hospital practice	Pathology, BWH	10 weeks per year
Gastrointestinal Pathology	Hospital practice	Pathology, BWH	8 weeks per year
Endocrine Pathology	Hospital practice	Pathology, BWH	8 weeks per year
Fluorescence <i>in situ</i> hybridization (HER2 FISH)	Hospital practice	Pathology, BWH	10 weeks per year

Clinical Innovations

In order to provide objective and more widely available methods for the diagnosis of soft tissue tumors, I have been the first or among the first to develop protein-based diagnostic biomarkers that correlate with molecular genetic alterations, which can be evaluated by immunohistochemistry. Many of these markers have dramatically changed clinical practice and have become standard of care internationally for confirming the diagnosis of a wide range of tumor types. Examples include:

- INI1 (SMARCB1) for epithelioid sarcoma and epithelioid malignant peripheral nerve sheath tumor
- MUC4 for low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma
- RB1 (retinoblastoma) for spindle cell/pleomorphic lipoma, mammary-type myofibroblastoma, and cellular angiofibroma
- SDHA for gastrointestinal stromal tumors with *SDHA* mutations
- SATB2 for osteosarcoma
- STAT6 for solitary fibrous tumor
- ROS1 for inflammatory myofibroblastic tumors with *ROS1* rearrangements
- ALK for epithelioid fibrous histiocytoma
- CAMTA1 for epithelioid hemangioendothelioma
- Histone H3 with lysine 27 trimethylation for malignant peripheral nerve sheath tumor

Jason L. Hornick, M.D., Ph.D.

- ETV4 for sarcomas with *CIC* rearrangements
- FOSB for pseudomyogenic hemangioendothelioma

I have been instrumental in helping to define diagnostic criteria for and clinical behavior of poorly characterized and previously unrecognized soft tissue tumor types. These tumor types are now recognized globally and have been incorporated into the World Health Organization classification. These include myoepithelial tumors of soft tissue, histologically and immunophenotypically distinctive neoplasms that range from benign myoepitheliomas and mixed tumors to malignant myoepithelial carcinomas; intestinal perineurioma, an intramucosal proliferation of perineurial cells often associated with colorectal serrated polyps; sclerosing perivascular epithelioid cell tumor (PEComa), a distinctive variant of PEComa with a predilection for the pararenal retroperitoneum; hybrid schwannoma/perineurioma, a distinctive benign nerve sheath tumor unassociated with neurofibromatosis; pseudomyogenic hemangioendothelioma, a distinctive, rarely metastasizing vascular neoplasm that often presents as multifocal disease in different tissue planes of the limbs of young men; epithelioid inflammatory myofibroblastic sarcoma, an aggressive, usually intra-abdominal variant of inflammatory myofibroblastic tumor with distinctive histology, a unique pattern of ALK expression, and a characteristic gene fusion; and “pediatric-type” (now widely known as succinate dehydrogenase-deficient) gastrointestinal stromal tumors (GIST), a histologically distinctive subset of GIST that arise in the stomach, often metastasize to lymph nodes, and show dysregulation of the succinate dehydrogenase complex.

Report of Education of Patients and Service to the Community

Patient Educational Material

1. **Hornick JL**, Lazar AJF. Gastrointestinal Stromal Tumor: Understanding your GIST Pathology Report [educational booklet and online resource]. GIST Support International, 2010.

Report of Scholarship

Peer Reviewed Publications in print or other media

Research Investigations

1. Akileswaran L, Alic M, Clark EK, **Hornick JL**, Gold M. Isolation and transformation of uracil auxotrophs of the lignin-degrading basidiomycete *Phanerochaete chrysosporium*. *Curr Genet* 1993;23:351-356.
2. Hu P, Glasky MS, Yun A, Alauddin MM, **Hornick JL**, Khawli LA, Epstein AL. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. *Hum Antibod Hybrid* 1995;6:57-67.
3. Epstein AL, Khawli LA, **Hornick JL**, Taylor CR. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. *Cancer Res* 1995;55:2673-2680.

Jason L. Hornick, M.D., Ph.D.

4. Khawli LA, Milkie MN, **Hornick JL**, Glasky MS, Sharifi J, Hu P, Epstein AL. Production of immunoreactive F(ab')₂ fragments in high yield from murine IgG₁ monoclonal antibodies. *Int J Biochromat* 1996;2:89-99.
5. Hu P, **Hornick JL**, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. *Cancer Res* 1996;56:4998-5004.
6. Khawli LA, **Hornick JL**, Sharifi J, Epstein AL. Improving the chemotherapeutic index of IUDR using a vasoactive immunoconjugate. *Radiochim Acta* 1997;79:83-86.
7. **Hornick JL**, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin 2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. *Blood* 1997;89:4437-4447.
8. Funakoshi S, Hirano A, Beckwith M, Asai O, Jorgensen G, Tian Z-g, **Hornick JL**, Hu P, Khawli LA, Epstein AL, Longo DL, Murphy WJ. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines *in vitro* and *in vivo*. *Blood* 1997;90:3160-3166.
9. **Hornick JL**, Sharifi J, Hu P, Khawli LA, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. *Cancer Biother Radiopharm* 1998;13:255-268.
10. **Hornick JL**, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a monoclonal antibody/interleukin 2 fusion protein directed against DNA enhances the uptake of therapeutic molecules to solid tumors. *Clin Cancer Res* 1999;5:51-60.
11. **Hornick JL**, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, Mizokami MM, Epstein AL. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. *J Nucl Med* 2000;41:355-362.
12. Nascimento AF, Ruiz R, **Hornick JL**, Fletcher CDM. Calcifying fibrous 'pseudotumor': clinicopathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. *Int J Surg Pathol* 2002;10:189-196.
13. **Hornick JL**, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. *Am J Clin Pathol* 2002;117:188-193; **with editorial**.
14. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, **Hornick J**, Salgia R, Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. *Clin Cancer Res* 2003;9:5880-5887.
15. **Hornick JL**, Fletcher CDM. Myoepithelial tumors of soft tissue: A clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. *Am J Surg Pathol* 2003;27:1183-1196.

16. **Hornick JL**, Fletcher CDM. Cutaneous myoepithelioma: A clinicopathologic and immunohistochemical study of 14 cases. *Hum Pathol* 2004;35:14-24.
17. Mutinga ML, Odze RD, Wang HH, **Hornick JL**, Farraye FA. The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. *Inflam Bowel Dis* 2004;10:215-219.
18. Medeiros F, Corless CL, Duensing A, **Hornick JL**, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CDM. Kit-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. *Am J Surg Pathol* 2004;28:889-894.
19. Odze RD, Farraye FA, Hecht JL, **Hornick JL**. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. *Clin Gastro Hepatol* 2004;2:534-541; **with editorial**.
20. Duensing A, Joseph NE, Medeiros F, Smith F, **Hornick JL**, Heinrich MC, Corless CL, Demetri GD, Fletcher CDM, Fletcher JA. Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). *Cancer Res* 2004;64:5127-5131.
21. **Hornick JL**, Jaffe ES, Fletcher CDM. Extranodal histiocytic sarcoma: Clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. *Am J Surg Pathol* 2004;28:1133-1144.
22. **Hornick JL**, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CDM. Pleomorphic liposarcoma: Clinicopathologic analysis of 57 cases. *Am J Surg Pathol* 2004;28:1257-1267.
23. **Hornick JL**, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. *Am J Surg Pathol* 2005;29:372-380.
24. **Hornick JL**, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. *Am J Surg Pathol* 2005;29:381-389.
25. **Hornick JL**, Fletcher CDM. Intraabdominal cystic lymphangiomas obscured by marked superimposed reactive changes: Clinicopathological analysis of a series. *Hum Pathol* 2005;36:426-432.
26. **Hornick JL**, Fletcher CDM. Soft tissue perineurioma: Clinicopathologic analysis of 81 cases including those with atypical histologic features. *Am J Surg Pathol* 2005;29:845-858.
27. **Hornick JL**, Fletcher CDM. Intestinal perineuriomas: clinicopathologic definition of a new anatomic subset in a series of 10 cases. *Am J Surg Pathol* 2005;29:859-865.

Jason L. Hornick, M.D., Ph.D.

28. **Hornick JL**, Farraye FA, Odze RD. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma. *Am J Surg Pathol* 2006;30:28-35.
29. Hahn HP, Bundock EA, **Hornick JL**. Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics. *Am J Clin Pathol* 2006;125:203-208.
30. **Hornick JL**, Fletcher CDM. Intra-articular nodular fasciitis – a rare lesion: Clinicopathologic analysis of a series. *Am J Surg Pathol* 2006;30:237-241.
31. Carter MR, **Hornick JL**, Lester S, Fletcher CDM. Spindle cell (sarcomatoid) carcinoma of the breast: A clinicopathologic and immunohistochemical analysis of 29 cases. *Am J Surg Pathol* 2006;30:300-309.
32. Carrasco DR, Fenton T, Protopopova M, Sukhdeo K, German M, You M, Divicio D, Nogueira C, Stommel J, Fletcher CD, **Hornick JL**, Cavenie W, Funary F, DePinho RA. The PTEN and INK4a/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. *Cancer Cell* 2006;9:379-390.
33. Reis-Filho JS, Pinheiro C, Lambros MBK, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, **Hornick JL**, Pereira EM, Baltazar F, Fletcher CDM, Ashworth A, Lakhani SR, Schmitt FC. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. *J Pathol* 2006;209:445-453.
34. Santagata S, **Hornick JL**, Ligon KL. Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. *Am J Surg Pathol* 2006;30:1613-1618.
35. Savage K, Lambros MBK, Robertson D, Jones RL, Jones C, Mackay A, James M, **Hornick JL**, Pereira EM, Milanezi F, Fletcher CDM, Schmitt FC, Ashworth A, Reis-Filho JS. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphological, ultrastructural, immunohistochemical and *in situ* hybridisation analysis. *Clin Cancer Res* 2007;13:90-101.
36. **Hornick JL**, Farraye FA, Odze RD. Clinicopathologic and immunohistochemical study of small apparently “de novo” colorectal adenocarcinomas. *Am J Surg Pathol* 2007;31:207-215.
37. Coffin CM, **Hornick JL**, Zhou H, Fletcher CDM. Gardner fibroma: A clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. *Am J Surg Pathol* 2007;31:410-416.
38. **Hornick JL**, Fletcher CDM. Cellular neurothekeoma: Detailed characterization in a series of 133 cases. *Am J Surg Pathol* 2007;31:329-340.
39. Srivastava A, **Hornick JL**, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. *Am J Gastroenterol* 2007;102:483-493; **with editorial**.

Jason L. Hornick, M.D., Ph.D.

40. Coffin CM, **Hornick JL**, Fletcher CDM. Inflammatory myofibroblastic tumor: Comparison of clinicopathologic, histologic, and immunohistochemical features and ALK expression in atypical and aggressive cases. *Am J Surg Pathol* 2007;31:509-520.
41. Sholl LM, **Hornick JL**, Pinkus JL, Pinkus GS, Padera RF. Immunohistochemical analysis of langerin in langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. *Am J Surg Pathol* 2007;31:947-952.
42. Santagata S, Ligon KL, **Hornick JL**. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. *Am J Surg Pathol* 2007;31:836-845.
43. Hahn HP, **Hornick JL**. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. *Am J Surg Pathol* 2007;31:1669-1676.
44. Yu H, Pinkus GS, **Hornick JL**. Diffuse membranous immunoreactivity for D2-40 (podoplanin) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. *Am J Clin Pathol* 2007;128:767-775.
45. Ito H, **Hornick JL**, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena cava: Impact of multidisciplinary management. *Ann Surg Oncol* 2007;14:3534-3541.
46. Yu H, Gibson JA, Pinkus GS, **Hornick JL**. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. *Am J Clin Pathol* 2007;128:776-782.
47. Hollmann TJ, Brenn T, **Hornick JL**. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. *Am J Surg Pathol* 2008;32:139-145.
48. **Hornick JL**, Mino-Kenudson M, Lauwers GY, Liu W, Goyal R, Odze RD. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. *Am J Gastroenterol* 2008;103:38-47.
49. **Hornick JL**, Fletcher CDM. Sclerosing PEComa: Clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum. *Am J Surg Pathol* 2008;32:493-501.
50. Liegl B, **Hornick JL**, Fletcher CDM. Primary cutaneous PEComa: Distinctive clear cell lesions of skin. *Am J Surg Pathol* 2008;32:608-614.
51. Cho NL, Redston M, Zauber AG, Carothers AM, **Hornick J**, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the Adenoma Prevention with Celecoxib trial. *Cancer Prev Res* 2008;1:21-31; **with editorial.**

52. Gasparotto D, Rossi S, Bearzi I, Doglioni C, Marzotto A, **Hornick JL**, Grizzo A, Sartor C, Moldolesi A, Sciot R, Debiec-Rychter M, Dei Tos AP, Maestro R. Multiple primary sporadic gastrointestinal stromal tumors (GIST) in the adult: An underestimated entity. *Clin Cancer Res* 2008;14: 5715-5721.
53. Wang VS, **Hornick JL**, Sepulveda JA, Mauer R, Poneros JM. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: A 20-year experience. *Gastrointest Endosc* 2009;69:777-783; **with editorial**.
54. Liegl B, **Hornick JL**, Antonescu CR, Corless CL, Fletcher CDM. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: A novel form of tumor progression. *Am J Surg Pathol* 2009;33:218-226.
55. Wang W, **Hornick JL**, Mallipeddi R, Zelger BG, Rother JD, Yang D, Lev DC, Trent JC, Prieto VJ, Brenn T, Calonje E, Lazar AJ. Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: A series of 5 cases with molecular analysis. *Am J Dermatopathol* 2009;31:297-300.
56. Marsee DK, Pinkus GS, **Hornick JL**. Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. *Appl Immunohistochem Mol Morphol* 2009;17:102-107.
57. Liegl B, **Hornick JL**, Corless CL, Fletcher CDM. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. *Am J Surg Pathol* 2009;33:437-446.
58. Kulke MH, **Hornick JL**, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. *Clin Cancer Res* 2009;15:338-345.
59. Yang Q, **Hornick JL**, Granter SR, Wang LC. Merkel cell carcinoma: Lack of KIT positivity and implications for the use of imatinib mesylate. *Appl Immunohistochem Mol Morphol* 2009;17:276-281.
60. Chang MC, Vargas SO, **Hornick JL**, Hirsch MS, Crum CP, Nucci MR. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. *Int J Gynecol Pathol* 2009;28:347-355.
61. **Hornick JL**, Dal Cin P, Fletcher CDM. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. *Am J Surg Pathol* 2009;33:542-550.
62. Srivastava A, **Hornick JL**. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. *Am J Surg Pathol* 2009;33:626-632.

63. Gibson JA, **Hornick JL**. Mucosal Schwann cell "hamartoma": Clinicopathologic study of 26 neural colorectal polyps distinct from neurofibromas and mucosal neuromas. *Am J Surg Pathol* 2009;33:781-787.
64. Brock JE, **Hornick JL**, Richardson A, Dillon D, Lester SC. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. *Am J Clin Pathol* 2009;132:396-401.
65. Boland JM, Folpe AL, **Hornick JL**, Grogg KL. Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: Diagnostic and histogenetic implications. *Am J Surg Pathol* 2009;33:1225-1229.
66. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, **Hornick JL**, Shivdasani RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer: Implications for clinical and pathology practice. *Clin Cancer Res* 2009;15:4665-4673.
67. **Hornick JL**, Bundock EA, Fletcher CDM. Hybrid schwannoma/perineurioma: Clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. *Am J Surg Pathol* 2009;33:1554-1561.
68. Long KB, **Hornick JL**. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. *Hum Pathol* 2009;40:1768-1773.
69. Coco D, Hirsch MS, **Hornick JL**. Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract. *Am J Surg Pathol* 2009;33:1795-1801.
70. Sholl LM, Long KB, **Hornick JL**. SOX2 expression in pulmonary non-small cell and neuroendocrine carcinomas. *Appl Immunohistochem Mol Morphol* 2010;18:55–61.
71. Laury AR, **Hornick JL**, Perets R, Corson J, Drapkin R, Hirsch MS. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. *Am J Surg Pathol* 2010;34:627-635.
72. Mino-Kenudson M, Chirieac LR, Law K, **Hornick JL**, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clin Cancer Res* 2010;16:1561-1571.
73. Long KB, Srivastava A, Hirsch MS, **Hornick JL**. PAX8 expression in well-differentiated pancreatic endocrine tumors: Correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. *Am J Surg Pathol* 2010;34:723-729.
74. Dorfman DM, **Hornick JL**, Shahsafaei A, Freeman GJ. The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4 (TIM-3, TIM-4), are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. *Hum Pathol* 2010;41:1486-1494.

Jason L. Hornick, M.D., Ph.D.

75. Yen EH*, **Hornick JL***, Dehlink E, Dokter M, Baker A, Fiebigler E, Nurko S. Comparative analysis of FcεRI expression patterns in patients with eosinophilic and reflux esophagitis. *J Pediatr Gastroenterol Nutr* 2010;51:584-592.
76. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, **Hornick JL**. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinomas. *Am J Surg Pathol* 2010;34:1193-1198.
77. Mariño-Enríquez A, Fletcher CDM, Dal Cin P, **Hornick JL**. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: Clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. *Am J Surg Pathol* 2010;34:1122-1131.
78. Butrynski JE, D'Adamo DR, **Hornick JL**, Dal Cin PS, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. *N Engl J Med* 2010;363:1727-1733.
79. Hwang DG, Qian X, **Hornick JL**. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. *Am J Clin Pathol* 2011;135:448-453.
80. Coco DP, Goldblum JR, **Hornick JL**, Lauwers GY, Montgomery E, Srivastava A, Wang H, Odze RD. Interobserver variability in the diagnosis of crypt dysplasia in Barrett's esophagus. *Am J Surg Pathol* 2011;35:45-54.
81. Saab ST, **Hornick JL**, Fletcher CD, Olson S, Coffin CM. IgG4 plasma cells in inflammatory myofibroblastic tumor: Inflammatory marker or pathogenic link? *Mod Pathol* 2011;24:606-612.
82. **Hornick JL**, Fletcher CD. Pseudomyogenic hemangioendothelioma: A distinctive, often multicentric tumor with indolent behavior. *Am J Surg Pathol* 2011;35:190-201.
83. Mariño-Enríquez A, Wang W, Roy A, Lopez-Terrada D, Lazar AJF, Fletcher CDM, Coffin CM, **Hornick JL**. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. *Am J Surg Pathol* 2011;35:135-144.
84. Sakharpe A, Lahat G, Gulamhusein T, Liu P, Bolshakov S, Nguyen T, Zhang P, Belushov R, Young E, Xie X, Rao P, **Hornick JL**, Lazar AJ, Pollock RE, Lev D. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: Clinicopathological variables, molecular markers, and a new experimental model. *Oncologist* 2011;16:512-522.
85. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PLM, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, **Hornick JL**, NIH Pediatric and wild-type GIST Clinic, O'Sullivan M, de Krijger RR, Dinjens WNM, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking *KIT* and *PDGFRA* mutations. *Proc Natl Acad Sci USA* 2011;108:314-318.

Jason L. Hornick, M.D., Ph.D.

86. Manion EM, **Hornick JL**, Lester SC, Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. *Am J Clin Pathol* 2011;135:845-851.
87. Foo WC, Cruise MW, Wick MR, **Hornick JL**. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. *Am J Clin Pathol* 2011;135:839-844.
88. Trombetta D, Magnusson L, von Steyern FV, **Hornick JL**, Fletcher CDM, Mertens F. Translocation t(7;19)(q22;q13) – a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? *Cancer Genet* 2011;204:211-215.
89. Rege TA, Wagner AJ, Corless CL, Heinrich MC, **Hornick JL**. “Pediatric-type” gastrointestinal stromal tumors in adults: Distinctive histology predicts genotype and clinical behavior. *Am J Surg Pathol* 2011;35:495-504.
90. Doyle LA, Möller E, Dal Cin P, Fletcher CD, Mertens F, **Hornick JL**. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. *Am J Surg Pathol* 2011;35:733-741.
91. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda MF, **Hornick JL**, Drapkin R, Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. *Am J Surg Pathol* 2011;35:816-826.
92. Oyoshi MK, Elkhali A, Scott JE, Wurbel MA, **Hornick JL**, Campbell JJ, Geha RS. Epicutaneous challenge of orally immunized mice redirects antigen-specific gut-homing T cells to the skin. *J Clin Invest* 2011;121:2210-2220.
93. Möller E, **Hornick JL**, Magnusson L, Veerla S, Domanski HA, Mertens F. *FUS-CREB3L2/L1* positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. *Clin Cancer Res* 2011;17:2646-2656.
94. Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, **Hornick JL**, Lazar AJ, Pisters P, Pollock RE, Lev D. Pleomorphic liposarcoma: Clinical observations and molecular variables. *Cancer* 2011;117:5359-5369.
95. Hamilton MJ, **Hornick JL**, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations. *J Allergy Clin Immunol* 2011;128:147-152.
96. Herrera AF, Soriano G, Bellizzi AM, **Hornick JL**, Ho VT, Ballen KK, Baden LR, Cutler CS, Antin JH, Soiffer RJ, Marty FM. Cord colitis syndrome in cord-blood stem-cell transplantation. *N Engl J Med* 2011;365:815-824.
97. Xie X, Ghadimi MP, Young ED, Belousov R, Zhu Q, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, **Hornick JL**, Lazar AJ, Lev D. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. *Clin Cancer Res* 2011;17:5901-5912.

Jason L. Hornick, M.D., Ph.D.

98. Barletta JA, Bellizzi AM, **Hornick JL**. Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome. *Am J Surg Pathol* 2011;35:1505-1511.
99. Byers R, **Hornick JL**, Tholouli E, Kutok J, Rodig S. Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry. *Appl Immunohistochem Mol Morphol* 2012;20:37-40.
100. Abraham JA, Weaver MJ, **Hornick JL**, Zurakowski D, Ready JE. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. *J Bone Joint Surg Am* 2012;94:736-744.
101. Qian X, **Hornick JL**, Cibas ES, Dal Cin P, Domanski HA. Angiomatoid fibrous histiocytoma: A series of five cytologic cases with literature review and emphasis on diagnostic pitfalls. *Diagn Cytopathol* 2012;40 Suppl 2:E86-93.
102. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, **Hornick JL**, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. *Ann Surg Oncol* 2012;19:1944-1953.
103. Stockman DL, Miettinen M, Suster S, Spagnolo D, Dominguez-Malagon H, **Hornick JL**, Adsay V, Chou PM, Amanuel B, Vantuinen P, Zambrano EV. Malignant gastrointestinal neuroectodermal tumor: Clinicopathologic, immunohistochemical, ultrastructural and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. *Am J Surg Pathol* 2012;36:857-868.
104. Shinagare AB, Jagannathan JP, Krajewski KM, Zukotynski K, Butrynski J, **Hornick JL**, Ramaiya NH. Esophageal gastrointestinal stromal tumor: Report of 7 patients. *Cancer Imaging* 2012;12:100-108.
105. Yurgelun MB, Goel A, **Hornick JL**, Sen A, Turgeon DK, Ruffin MT, Marcon NE, Baron JA, Bresalier RS, Syngal S, Brenner DE, Boland CR, Stoffel EM. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. *Cancer Prev Res* 2012;5:574-582.
106. Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, **Hornick JL**, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: Data from U.S. nationwide prospective cohort studies. *Arch Surg* 2012;147:715-723.
107. Look Hong NJ, Pandalai PK, **Hornick JL**, Shekar PM, Harmon DC, Chen YL, Butrynski JE, Baldini EH, Raut CP. Cardiac angiosarcoma management and outcomes: 20-year single institution experience. *Ann Surg Oncol* 2012;19:2707-2715.
108. McKay KM, Doyle LA, Lazar AJ, **Hornick JL**. Expression of ERG, and Ets family transcription factor, distinguishes cutaneous angiosarcoma from histologic mimics. *Histopathology* 2012;61:989-991.

109. Liszewski MC, Sahni VA, Shyn PB, Friedman S, **Hornick JL**, Erturk SM, Morteale KJ. MDCT enterography assessment of the ileal-anal pouch: Descriptive radiologic analysis with endoscopic and pathologic correlation. *J Comput Assist Tomogr* 2012;36:394-399.
110. Shinagare AB, Krajewski KM, **Hornick JL**, Zukotynski K, Jagannathan JP, Ramaiya NH. MRI for evaluation of myeloid sarcoma in adults: A single-institution 10-year experience. *AJR Am J Roentgenol* 2012;199:1193-1198.
111. Doyle LA, Wang W, Dal Cin P, Lopez-Terrada D, Mertens F, Lazar AJ, Fletcher CD, **Hornick JL**. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: Association with *FUS* gene rearrangement. *Am J Surg Pathol* 2012;36:1444-1451.
112. Wang WL, Patel NR, Caragea M, Hogendoorn PC, Lopez-Terrada D, **Hornick JL**, Lazar AJ. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. *Mod Pathol* 2012;25:1378-1383.
113. Doyle LA, Nelson D, Heinrich MC, Corless CL, **Hornick JL**. Loss of SDHB expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumors: A comprehensive genotype-phenotype correlation study. *Histopathology* 2012;61:801-809.
114. Chen BJ, Mariño-Enríquez A, Fletcher CD, **Hornick JL**. Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: An immunohistochemical study with diagnostic implications. *Am J Surg Pathol* 2012;36:1119-1128.
115. Brcic L, Sherer CK, Shuai Y, **Hornick JL**, Chirieac L, Dacic S. Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2. *Am J Clin Pathol* 2012;138:712-718.
116. Sioletic S, Dal Cin P, Fletcher CD, **Hornick JL**. Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: Analysis of 56 cases. *Histopathology* 2013;62:287-293.
117. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, **Hornick JL**. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. *Mod Pathol* 2013;26:289-294.
118. Koch MR, Jagannathan JP, Shinagare AB, Krajewski KM, Raut CP, **Hornick JL**, Ramaiya NH. Imaging features of primary anorectal gastrointestinal stromal tumors with clinical and pathologic correlation. *Cancer Imaging* 2013;12:557-565.
119. Al-Zaid T, Wang WL, Lopez-Terrada D, Lev D, **Hornick JL**, Hafeez Diwan A, Fletcher CD, Lazar AJ. Pleomorphic fibroma and dermal atypical lipomatous tumor: Are they related? *J Cutan Pathol* 2013;40:379-384.
120. Rao P, Lahat G, Arnold C, Gavino AC, Lahat S, **Hornick JL**, Lev D, Lazar AJ. Angiosarcoma: A tissue microarray study with diagnostic implications. *Am J Dermatopathol* 2013;35:432-437.

121. Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, **Hornick JL**, Lazar AJ, Hunt KK, Anderson ML, Creighton CJ, Lev D, Pollock RE. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. *Ann Surg Oncol* 2013;20:2364-2372.
122. Sholl LM, Weremowicz S, Grey SW, Wong KK, Chirieac L, Lindeman NI, **Hornick JL**. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. *J Thorac Oncol* 2013;8:322-328; **with editorial**.
123. Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D, **Hornick JL**, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: Clinical and molecular observations. *Cancer* 2013;119:1868-1877.
124. Antonescu CR, Romeo S, Zhang L, Nafa K, **Hornick JL**, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos AP, Fletcher CD. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype - a diagnostic pitfall. Morphologic and molecular characterization of 8 cases occurring either de-novo or after imatinib therapy. *Am J Surg Pathol* 2013;37:385-392.
125. Kamran S, Howard S, Shinagare A, Krajewski K, Jagannathan J, **Hornick JL**, Ramaiya N. Malignant peripheral nerve sheath tumors: Prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location. *Eur J Surg Oncol* 2013;39:46-52.
126. Herfs M, Vargas SO, Yamamoto Y, Howitt BE, Nucci MR, **Hornick JL**, Mckeon FD, Xian W, Crum CP. A novel blueprint for “top down” differentiation defines the cervical squamocolumnar junction during development, reproductive life and neoplasia. *J Pathol* 2013;229:460-468.
127. Bartnikas LM, Gurish MF, Burton OT, Leisten S, Janssen E, Oettgen HC, Beaupré J, Lewis CN, Austen KF, Schulte S, **Hornick JL**, Geha RS, Oyoshi MK. Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food anaphylaxis. *J Allergy Clin Immunol* 2013;131:451-460.
128. Leisten S, Oyoshi MK, Galand C, **Hornick JL**, Gurish MF, Geha RS. Development of skin lesions in filaggrin-deficient mice is dependent on adaptive immunity. *J Allergy Clin Immunol* 2013;131:1247-1250.
129. Ryan RJ, Akin C, Castells M, Wills M, Selig MK, Nielsen GP, Ferry JA, **Hornick JL**. Mast cell sarcoma: A rare and potentially under-recognized diagnostic entity with specific therapeutic implications. *Mod Pathol* 2013;26:533-543.
130. Jo VY, Antonescu CR, Zhang L, Dal Cin P, **Hornick JL**, Fletcher CD. Cutaneous syncytial myoepithelioma: Clinicopathologic characterization in a series of 38 cases. *Am J Surg Pathol* 2013;37:710-718.

Jason L. Hornick, M.D., Ph.D.

131. Beadling C, Patterson J, Justusson E, Nelson D, Pantaleo MA, **Hornick JL**, Chacon M, Corless CL, Heinrich MC. Gene expression of the IGF family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. *Cancer Med* 2013;2:21-31.
132. Conner JR, **Hornick JL**. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumors. *Histopathology* 2013;63:36-49.
133. Khandekar MJ, Raut CP, **Hornick JL**, Wang Q, Alexander BM, Baldini EH. Paratesticular liposarcoma: Unusual patterns of recurrence and importance of margins. *Ann Surg Oncol* 2013;20:2148-2155.
134. Kamran SC, Shinagare AB, Howard SA, Nishino M, **Hornick JL**, Krajewski KM, Ramaiya NH. Intrathoracic malignant peripheral nerve sheath tumors: Imaging features and implications for management. *Radiol Oncol* 2013;47:230-238.
135. Mason EF, Sadow PM, Wagner AJ, Remillard SP, Flood TA, Belanger EC, **Hornick JL**, Barletta JA. Identification of succinate dehydrogenase-deficient bladder paragangliomas. *Am J Surg Pathol* 2013;37:1612-1618.
136. Adackapara CA, Sholl LM, Barletta JA, **Hornick JL**. Immunohistochemistry using the BRAF V600E mutation specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. *Histopathology* 2013;63:187-193.
137. Mason EF, **Hornick JL**. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: Implications for mechanisms of tumorigenesis. *Mod Pathol* 2013;26:1492-1497.
138. Doyle LA, **Hornick JL**, Fletcher CD. PEComa of the gastrointestinal tract: Clinicopathologic study of 35 cases with evaluation of prognostic parameters. *Am J Surg Pathol* 2013;37:1769-1782.
139. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, **Hornick JL**, Chirieac L, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyaon C, Cassidy AJ, DeAngelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines B, Sathayanayanan S, Rodig S, and Aster JC. Gauging NOTCH1 activation in cancer using immunohistochemistry. *PLoS One* 2013;8:e67306.
140. Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, Brosjo O, Domanski HA, Larsson O, Sciort R, Debiec-Rychter M, **Hornick JL**, Mandahl N, Nord KH, Mertens F. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, non-random secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. *Genes Chromosomes Cancer* 2013;52:873-886.

141. Bhatt AS, Freeman SS, Herrera AF, Pedomallu CS, Gevers D, Duke F, Jung J, Michaud M, Walker BJ, Young S, Earl AM, Kostic AD, Ojesina AI, Hasserjian R, Ballen KK, Chen YB, Soriano G, Antin JH, Soiffer RJ, Baden LR, Garrett WS, **Hornick JL**, Marty FM, Meyerson M. Sequence-based discovery of *Bradyrhizobium enterica* in cord colitis syndrome. *N Engl J Med* 2013; 369:517-528.
142. Thum C, Husain EA, Mulholland K, **Hornick JL**, Brenn T. Atypical fibroxanthoma with pseudoangiomatous features: A histological and immunohistochemical mimic of cutaneous angiosarcoma. *Ann Diagn Pathol* 2013;17:502-507.
143. Turimani SH, Shinagare AB, Hargreaves J, Jagannathan JP, **Hornick JL**, Wagner AJ, Ramaiya NK. Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. *Am J Roentgenol* 2014;202:252-258.
144. Doyle LA, Vivero M, Fletcher CD, Mertens F, **Hornick JL**. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. *Mod Pathol* 2014;27:390-395.
145. Keung E, **Hornick JL**, Baldini EH, Bertagnolli M, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. *J Am Coll Surg* 2014;218:206-217.
146. Cheng JM, Tirumani SH, Shinagare AB, Jagannathan JP, **Hornick JL**, Raut CP, Ramaiya NH. MDCT of primary, locally advanced and metastatic duodenal gastrointestinal stromal tumors (GISTs): A single institution study of 25 patients with review of literature. *Clin Radiol* 2014;69:137-144.
147. Mariño-Enríquez A, **Hornick JL**, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: A comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. *Cancer Cytopathol* 2014;122:128-137.
148. Elias KM, Labidi-Galy SI, Vitonis AF, **Hornick JL**, Doyle LA, Hirsch MS, Cramer DW, Drapkin RI. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. *Gynecol Oncol* 2014;132:328-333.
149. Abadin SS, Ayala-Ramirez M, Jimenez C, Dickson PV, Liang Y, Lazar AJ, **Hornick JL**, Cotton M, Sui D, Rich T, Lee JE, Grubbs E, Perrier ND. Impact of surgical resection for subdiaphragmatic paragangliomas. *World J Surg* 2014;38:733-741.
150. Patel SA, Chen YH, **Hornick JL**, Zukerberg LR, Bleday R, Shellito PC, Hong TS, Mamon HJ. Early stage rectal cancer: Clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection. *Dis Colon Rectum* 2014;57:449-459.
151. Gordon RW, Tirumani SH, Kurra V, Shinagare AB, Jagannathan JP, **Hornick JL**, Ramaiya NH. MRI, MDCT features and clinical outcome of extremity leiomyosarcomas: Experience in 47 patients. *Skeletal Radiol* 2014;43:615-622.

Jason L. Hornick, M.D., Ph.D.

152. Stockman DL, **Hornick JL**, Deavers MT, Lev DC, Lazar AJ, Wang WL. ERG and FLI1 protein expression in epithelioid sarcoma. *Mod Pathol* 2014;27:496-501.
153. Sood S, Baheti A, Shinagare AB, Jagannathan JP, **Hornick JL**, Ramaiya NH, Tirumani SH. Imaging features of primary and metastatic alveolar soft part sarcoma: A single institute experience of 25 patients. *Br J Radiol* 2014;87:20130719.
154. Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, **Hornick JL**. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. *Am J Surg Pathol* 2014;38:832-843.
155. Yurgelun MB, **Hornick JL**, Curry VK, Ukaegbu CI, Brown EK, Hiller E, Chittenden A, Goldberg JE, Syngal S. Therapy-associated polyposis as a late sequela of cancer treatment. *Clin Gastroenterol Hepatol* 2014;12:1046-1050.
156. Vivero M, Doyle LA, Fletcher CDM, Mertens F, **Hornick JL**. GRIA2 is a novel diagnostic marker for solitary fibrous tumor identified through gene expression profiling. *Histopathology* 2014;65:71-80.
157. Wang R, Liu W, Helfer CM, Bradner JE, **Hornick JL**, Janicki SM, French CA, You J. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives the cellular transformation in NUT midline carcinoma. *Cancer Res* 2014;74:3332-3343.
158. Somarouthu B, Shinagare AB, Rosenthal MH, Tirumani H, Jagannathan JP, **Hornick JL**, Ramaiya NH, Tirumani SH. Multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma: Experience in 26 patients. *Br J Radiol* 2014;87(1038):20140123.
159. Weinreb I, Zhang L, Tirunagari LMS, Sung YS, Chen LC, Perez-Ordóñez B, Clarke BA, Skalova A, Chiosea SI, Seethala RR, Waggott D, Boutros PC, How C, Irish JC, Goldstein DP, Gilbert R, Din N, Assaad A, **Hornick JL**, Thompson LDR, Antonescu CR. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. *Genes Chromosomes Cancer* 2014;53:845-856.
160. Jo VY, **Hornick JL**, Qian X. Utility of brachyury in distinction of chordoma from cytomorphologic mimics in fine needle aspiration and core needle biopsy. *Diagn Cytopathol* 2014;42:647-652.
161. Conner JR, Cibas ES, **Hornick JL**, Qian X. WT-1/cytokeratin dual color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: An effective first-line test for workup of malignant effusions. *Cancer Cytopathol* 2014;122:586-595.
162. Kapoor N, Shinagare AB, Jagannathan JP, Shah SH, Krajewski KM, **Hornick JL**, Ramaiya NH. Clinical and radiologic features of extraskeletal myxoid chondrosarcoma including initial presentation, local recurrence, and metastases. *Radiol Oncol* 2014;48:235-242.

163. Renella R, Carnevale JC, Schneider KA, **Hornick JL**, Rana HQ, Janeway KA. Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. *Fam Cancer* 2014;13:507-511.
164. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, **Hornick JL**, Mautner V, Kehrer-Sawatski H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K. PRC2 loss amplifies Ras driven transcription and confers sensitivity to BRD4-based therapies. *Nature* 2014;514:247-251.
165. Wojcik JB, Bellizzi AB, Dal Cin P, Bredella MA, Fletcher CDM, Hornicek F, Deshpande V, **Hornick JL***, Nielsen GP*. Primary sclerosing epithelioid fibrosarcoma of bone: Analysis of a series. *Am J Surg Pathol* 2014;38:1538-1544.
166. Tirumani SH, Tirumani H, Jagannathan JP, Shinagare AB, **Hornick JL**, George S, Wagner AJ, Ramaiya NH. MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours. *Br J Radiol* 2014;87:20140476.
167. Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff D, Abedalthagafi M, Wen P, Reardon D, Dunn IF, Folkerth RD, Santagata S, Lindeman N, Ligon AH, Beroukhim R, **Hornick JL**, Alexander B, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. *Oncotarget* 2014;5:8083-8092.
168. Tirumani SH, Deaver P, Shinagare AB, Tirumani H, **Hornick JL**, George S, Ramaiya NH. Metastatic pattern of uterine leiomyosarcoma: Retrospective analysis of the predictors and outcome in 113 Patients. *J Gynecol Oncol* 2014;25:306-312.
169. Baheti AD, Tirumani SH, Shinagare AB, Rosenthal MH, Wolpin BM, **Hornick JL**, Ramaiya NH. Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: Retrospective study of 92 patients. *Abdom Imaging* 2014;39:1193-1201.
170. Pan E, Goldberg SI, Chen YL, Giraud C, **Hornick JL**, Nielsen GP, Hornicek FJ, Raut CP, DeLaney TF, Baldini EH. Role of post-operative radiation boost for soft tissue sarcomas with positive margins following pre-operative radiation and surgery. *J Surg Oncol* 2014;110:817-822.
171. Cheah AL, Billing SD, Goldblum JR, **Hornick JL**, Uddin N, Rubin BP. Spindle cell/pleomorphic lipomas of the face: An underrecognized diagnosis. *Histopathology* 2015;66:430-437.
172. Williamson SR, Eble JN, Amin MB, Gupta NS, Smith SC, Sholl LM, Montironi R, Hirsch MS, **Hornick JL**. Succinate dehydrogenase-deficient renal cell carcinoma: Detailed characterization of eleven tumors defining a unique subtype of renal cell carcinoma. *Mod Pathol* 2015;28:80-94.
173. Baheti A, Tirumani SH, Sewatkar R, Shinagare A, **Hornick JL**, Ramaiya N, Jagannathan J. Imaging features of primary and metastatic synovial sarcoma: A single institute experience of 78 patients. *Br J Radiol* 2015;88:20140608.

174. Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, **Hornick JL**, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. *Histopathology* 2015;66:627-638.
175. Jones RT, Abedalthagafi MS, Brahmandam M, Greenfield EA, Hoang MP, Louis DN, **Hornick JL**, Santagata S. Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. *Mod Pathol* 2015;28:596-606.
176. Nagymanyoki Z, Mutter G, **Hornick JL**, Cibas ES. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma. *Cancer Cytopathol* 2015;123:253-257.
177. **Hornick JL**, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. *Mod Pathol* 2015;28:732-739.
178. Hwang DH, Sun H, Rodig SJ, **Hornick JL**, Sholl LM. MYC protein expression correlates with MYC amplification in small cell lung carcinoma. *Histopathology* 2015;67:81-89.
179. Eilers G, Czaplinski JT, Mayeda1 M, Bahri1 N, Tao D, Zhu M, **Hornick JL**, Lindeman NI, Sicinska E, Wagner AJ, Fletcher JA, Mariño-Enriquez A. CDKN2A/p16 loss implicates CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans. *Mol Cancer Ther* 2015;14:1346-53.
180. Tirumani SH, Wagner AJ, Tirumani H, Shinagare AB, Jagannathan JP, **Hornick JL**, George S, Ramaiya NH. Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients. *Abdom Imaging* 2015;40:1248-54.
181. Calles A, Sholl LM, Rodig SJ, Pelton AK, **Hornick JL**, Butaney M, Lydon C, Dahlberg S, Oxnard GR, Jackman DM, Jänne PA. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS mutant lung adenocarcinoma. *Clin Cancer Res* 2015;21:2851-60.
182. Tirumani SH, Tirumani H, Jagannathan JP, Shinagare AB, **Hornick JL**, Ramaiya NH, Wagner AJ. Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients. *Eur J Surg Oncol* 2015;41:899-904.
183. Doyle LA, Mariño-Enríquez A, Fletcher CD, **Hornick JL**. ALK rearrangement and overexpression in epithelioid fibrous histiocytoma. *Mod Pathol* 2015;28:904-12; **with editorial**.
184. van der Horst MPJ, Marusic Z, **Hornick JL**, Luzar B, Brenn T. Morphologically low-grade spiradenocarcinoma: A clinicopathologic study of 19 cases with emphasis on outcome and MYB expression. *Mod Pathol* 2015;28:944-53.

Jason L. Hornick, M.D., Ph.D.

185. Tai R, Tirumani SH, Tirumani H, Shinagare AB, **Hornick JL**, Ramaiya NH. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and hematologic stem cell transplantation? Experience in 41 patients. *Br J Radiol* 2015;88:20140861.
186. Baheti AD, Sewatkar R, **Hornick JL**, Saboo SS, Jagannathan JP, Ramaiya NH, Tirumani SH. Imaging features of primary and recurrent intrathoracic synovial sarcoma: A single institute experience. *Clin Imaging* 2015;39:803-8.
187. Baheti AD, Shinagare AB, O'Neill AC, Krajewski KM, **Hornick JL**, George S, Ramaiya NH, Tirumani SH. MDCT and clinicopathological features of small bowel gastrointestinal stromal tumors in 102 patients: A single institute experience. *Br J Radiol* 2015;88:20150085.
188. Nayeb-Hashemi H, Desai A, Demchev V, Bronson RT, **Hornick JL**, Cohen DE, Ukomadu C. Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. *Biochem Biophys Res Commun* 2015;465:167-73.
189. Lee JC, Liao JY, Wu JM, Huang HY, Lo CY, **Hornick JL**, Qian X. Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry and molecular cytogenetic analysis. *Cancer Cytopathol* 2015;123:495-504.
190. Kerr DA, Arora KS, Mahadevan KK, **Hornick JL**, Krane JF, Rivera MN, Ting DT, Deshpande V, Faquin WC. Performance of a branch chain RNA *in situ* hybridization assay for the detection of high-risk human papillomavirus in head and neck squamous cell carcinoma. *Am J Surg Pathol* 2015;39:1643-52.
191. Sulahian R, Chen J, Arany Z, Jadhav U, Peng S, Rustgi AK, Bass AJ, Srivastava A, **Hornick JL**, Shivdasani RA. SOX15 governs transcription in human stratified epithelia and a subset of esophageal adenocarcinomas. *Cell Mol Gastroenterol Hepatol* 2015;1:598-609.e6.
192. Doyle LA, Fletcher CD, **Hornick JL**. Nuclear expression of CAMTA1 distinguishes epithelioid hemangiopericytoma from histologic mimics. *Am J Surg Pathol* 2016;40:94-102.
193. Griffin GK, Sholl LM, Lindeman N, Fletcher CDM, **Hornick JL**. Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF- κ B regulatory genes. *Mod Pathol* 2016;29:67-74.
194. Schaefer IM, Fletcher CDM, **Hornick JL**. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumor from histologic mimics. *Mod Pathol* 2016;29:4-13.
195. Xu J, Sun HH, Morgan EA, Pinkus GS, **Hornick JL**, Fletcher CDM, Freeman G, Rodig S. Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders. *Am J Surg Pathol* 2016;40:443-53.
196. Hung YP, Fletcher CDM, **Hornick JL**. Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: Imperfect specificity for Ewing sarcoma. *Mod Pathol* 2016;29:370-80.

197. Hwang DH, Sholl LM, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, **Hornick JL**, Kuo FC, Lindeman NI, Dong F. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. *J Thorac Oncol* 2016;11:496-503.
198. Wortman JR, Tirumani SH, Tirumani H, Shinagare AB, Jagannathan JP, **Hornick JL**, Ramaiya NH. Neoadjuvant radiation in primary extremity liposarcoma: Correlation of MRI features with histopathology. *Eur Radiol* 2016;26:1226-34.
199. Ordulu Z, Nucci MR, Dal Cin P, Hollowell M, Otis CN, **Hornick JL**, Park PJ, Kim TM, Quade BJ, Morton CC. Intravenous leiomyomatosis: An unusual intermediate between benign and malignant uterine smooth muscle tumors. *Mod Pathol* 2016;29:500-10.
200. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, **Hornick JL**, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ. Ipilimumab for patients who relapse after allogeneic transplantation. *N Engl J Med* 2016;375:143-53.
201. O'Neill AC, Shinagare AB, Kurra V, Tirumani SH, Jagannathan JP, Baheti AD, **Hornick JL**, George S, Ramaiya NH. Assessment of metastatic risk of gastric GIST based on treatment-naive CT features. *Eur J Surg Oncol* 2016;42:1222-8.
202. Hachey KJ, Gilmore DM, Armstrong KW, Harris SE, **Hornick JL**, Colson YL, Wee JO. Safety and feasibility of near infrared image-guided lymphatic mapping of regional lymph nodes in esophageal cancer. *J Thorac Cardiovasc Surg* 2016;152:546-54.
203. Liu Q, Tomaszewicz K, Hutchinson L, **Hornick JL**, Woda B, Yu H. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. *Virchows Arch* 2016;469:233-41.
204. Mangla S, Goldin AH, Singal G, **Hornick JL**, Hsu Blatman KS, Burakoff R, Chan WW. Endoscopic features and eosinophil density are associated with food impaction in adults with esophageal eosinophilia. *Dig Dis Sci* 2016;61:2578-84.
205. Schaefer IM, Minkovsky AF, **Hornick JL**. H3K27me3 immunohistochemistry highlights the inactivated X chromosome (Xi) and predicts sex in nonneoplastic tissues. *Histopathology* 2016;69:702-4.
206. Yang EJ, **Hornick JL**, Qian X. Fine needle aspiration of soft tissue perineurioma: A comparative analysis of cytomorphology and immunohistochemistry with benign and malignant mimics. *Cancer Cytopathol* 2016;124:651-8.
207. Mentzel T, Rütten A, Hantschke M, **Hornick JL**, Brenn T. S-100 protein expressing spindle cells in spindle cell lipoma: A diagnostic pitfall. *Virchows Arch* 2016;469:435-8.
208. Hung YP, Fletcher CDM, **Hornick JL**. Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. *Mod Pathol* 2016;29:1324-34.

209. Mason EF, **Hornick JL**. Conventional risk stratification fails to predict progression of succinate dehydrogenase-deficient gastrointestinal stromal tumors: A clinicopathologic study of 76 cases. *Am J Surg Pathol* 2016;40:1616-21.
210. Wortman JR, Tirumani SH, Jagannathan JP, Tirumani H, Shinagare AB, **Hornick JL**, Ramaiya NH. Primary extremity liposarcoma: MRI features, histopathology, and clinical outcomes. *J Comput Assist Tomogr* 2016;40:791-798.
211. O'Neill AC, Tirumani SH, Do WS, Keraliya AR, **Hornick JL**, Shinagare AB, Ramaiya NH. Metastatic patterns of solitary fibrous tumors: A single institution experience. *Am J Roentgenol* 2017;208:2-9.
212. Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, **Hornick JL**, Fletcher JA. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: Novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. *J Pathol* 2017;241:316-323.
213. Watkins JC, Yang EJ, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Syngal S, **Hornick JL**, Crum CP, Sholl LM, Howitt BE. Universal screening for mismatch repair deficiency in endometrial cancers to identify patients with Lynch Syndrome and Lynch-like Syndrome. *Int J Gynecol Pathol* 2017;36:115-127.
214. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, **Hornick JL**, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S. Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol* 2017;35:1086-1095.
215. Hofvander J, Arbajian E, Stenkula K, Lindkvist K, Larsson M, Nilsson J, Magnusson L, Vult von Steyern F, Rissler P, **Hornick JL**, Mertens F. Frequent low-level mutations of protein kinase D2 in angioliopoma. *J Pathol* 2017;241:578-582.
216. Schaefer IM, Agaimy A, Fletcher CDM, **Hornick JL**. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas. *Mod Pathol* 2017;30:539-548.
217. Hung YP, Fletcher CDM, **Hornick JL**. FOSB is a useful diagnostic marker for pseudomyogenic hemangi endothelioma. *Am J Surg Pathol* 2017;41:596-606.
218. Kao YC, Sung YS, Chen CL, Zhang L, Dickson B, Swanson D, Vaiyapuri S, Latif F, Alholle A, Huang SC, **Hornick JL**, Antonescu CR. ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements. *Genes Chromosomes Cancer* 2017;56:501-510.
219. Solomon IH, **Hornick JL**, Laga AC. Immunohistochemistry is rarely justified for the diagnosis of viral infections. *Am J Clin Pathol* 2017;147:96-104.

Jason L. Hornick, M.D., Ph.D.

220. Jo VY, Chau NG, **Hornick JL**, Krane JF, Sholl LM. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma. *Mod Pathol* 2017;30:650-659.
221. Schaefer IM, **Hornick JL**, Barysaukas CM, Raut CP, Patel SA, Royce TJ, Fletcher CDM, Baldini EH. Histologic appearance following pre-operative radiation therapy for soft tissue sarcoma: Assessment of the EORTC-STBSG response score. *Int J Radiat Oncol Biol Phys* 2017;98:375-383.
222. Epelboym Y, Keraliya AR, Tirumani SH, **Hornick JL**, Ramaiya NH, Shinagare AB. Differences in the imaging features and distribution of non-indolent and indolent mastocytosis: A single institution experience of 29 patients. *Clin Imaging* 2017;44:111-116.
223. Schaefer IM, **Hornick JL**, Sholl LM, Quade BJ, Nucci MR, Parra-Herran C. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour. *Histopathology* 2017;70:1138-1146.
224. Smith SC, Sirohi D, Ohe C, McHugh JB, **Hornick JL**, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, Hovelson D, Luthringer DJ, Martignoni G, Chen YB, Tomlins SA, Mehra R, Amin MB. A distinctive, low grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of SDH-deficient renal cell carcinoma. *Histopathology* 2017;71:42-52.
225. Drage MG, Tippayawong M, Agoston AT, Zheng Z, Bueno R, **Hornick JL**, Odze RD, Srivastava A. Morphological features and prognostic significance of ARID1A deficient esophageal adenocarcinomas. *Arch Pathol Lab Med* 2017;141:970-977.
226. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs C, Martin N, Getz G, Carter S, Mamon HJ, **Hornick JL**, Van Allen EM, D'Andrea AD. Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. *Clin Cancer Res* 2017;23:3214-3222.
227. Nicholls HT, **Hornick JL**, Cohen DE. Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 2017;313:G50-G61.
228. Paxton CN, O'Malley DP, Bellizzi AM, Alkapalan D, Fedoriw Y, **Hornick JL**, Perkins SL, South ST, Andersen EF. Genomic evaluation of juvenile xanthogranuloma shows structural changes are uncommon and relatively few in solitary lesions, while advanced cases may present more complexity. *Mod Pathol* 2017;30:1234-1240.
229. Charville GW, Wang WL, Ingram DR, Roy A, Thomas D, Patel RM, **Hornick JL**, van de Rijn M, Lazar AJ. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. *Mod Pathol* 2017;30:1312-1320.

Jason L. Hornick, M.D., Ph.D.

230. Andersen EF, Paxton CN, O'Malley DP, Louissaint Jr. A, **Hornick JL**, Griffin GK, Fedoriw Y, Kim YS, Weiss LM, Perkins SL, South ST. Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology. *Mod Pathol* 2017;30:1321-1334.
231. Shanmugam V, Craig JW, **Hornick JL**, Morgan EA, Pinkus GS, Pozdnyakova O. Cyclin D1 is expressed in neoplastic cells of Langerhans cell histiocytosis but not reactive Langerhans cell proliferations. *Am J Surg Pathol* 2017;41:1390-1396.
232. Solomon IH, Johncilla ME, **Hornick JL**, Milner DA. The utility of immunohistochemistry in mycobacterial infection: A proposal for multimodality testing. *Am J Surg Pathol* 2017;41:1364-1370.
233. Lee JP, Hung YP, O'Dorisio TM, Howe JR, **Hornick JL**, Bellizzi AM. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in pheochromocytomas and paragangliomas. *Histopathology* 2017;71:503-510.
234. Mito JK, Qian X, Doyle LA, **Hornick JL**, Jo VY. Role of histone H3 K27 trimethylation loss as a marker for malignant peripheral nerve sheath tumor in fine-needle aspiration and small biopsy specimens. *Am J Clin Pathol* 2017;148:179-189.
235. Troxell ML, Long T, **Hornick JL**, Ambaye AB, Jensen KC, CAP Immunohistochemistry Committee. Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. *Arch Pathol Lab Med* 2017;141:1402-1412.
236. Pretz JL, Barysaukas CM, George S, **Hornick JL**, Raut CP, Chen YE, Marcus KJ, Choy E, Hornicek F, Ready JE, DeLaney TF, Baldini EH. Localized adult Ewing sarcoma: Favorable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC/IE)-based multi-modality therapy. *Oncologist* 2017;22:1265-1270.
237. Hung YP, Lee JP, Bellizzi AM, **Hornick JL**. PHOX2B reliably distinguishes neuroblastoma among small round blue cell tumors. *Histopathology* 2017;71:786-794.
238. Busch EL, **Hornick JL**, Umeton R, Albayrak A, Lindeman NI, MacConnail LE, Garcia EP, Ducar M, Rebbeck TR. Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites. *Oncotarget* 2017;8:85680-85691.
239. Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. *Cell* 2017;171:950-965.
240. Morales-Oyarvide V*, Rubinson DA*, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, **Hornick JL**, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: Predictors of disease recurrence and survival. *Br J Cancer* 2017;117:1874-1882.

Jason L. Hornick, M.D., Ph.D.

241. Czeczok TW, Stashek KM, Maxwell JE, O'Dorisio TM, Howe JR, **Hornick JL**, Bellizzi AM. Clusterin in neuroendocrine epithelial neoplasms: Absence of expression in a well-differentiated tumor suggests a jejunoileal origin. *Appl Immunohistochem Mol Morphol* 2018;26:94-100.
242. Ferreira I, Kind P, Van Den Berghe I, Melly L, Offner F, **Hornick JL**, Brenn T. Melanocytic naevi with perineurial differentiation: A distinctive variant of neurotised naevi and a diagnostic pitfall with desmoplastic melanoma. *Histopathology* 2018;72:679-684.
243. Mito JK, Conner JR, **Hornick JL**, Cibas ES, Qian X. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the work-up of epithelioid malignant neoplasms in fine needle aspiration and small biopsy specimens. *Cancer Cytopathol* 2018;126:179-189.
244. Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, **Hornick JL**, Hezel AF, Koong AC, Wolpin BM. Alterations in main driver genes predict patient outcomes in resected pancreatic ductal adenocarcinoma. *JAMA Oncol* 2018;4:e173420.
245. Gerbaudo VH, Killoran JH, Kim CK, **Hornick JL**, Nowak JA, Enzinger PC, Mamon HJ. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: Correlation with histopathologic response. *Ann Nucl Med* 2018;32:165-174.
246. Tian X, Xu J, Fletcher CD, **Hornick JL**, Dorfman DM. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK-related, but not MYC- or p-STAT3-related cell signaling. *Mod Pathol* 2017, in press.
247. Williamson SR, **Hornick JL**, Eble JN, Gupta NS, Rogers CG, True L, Grignon DJ, Cheng L. Renal cell carcinoma with angioleiomyoma-like stroma and clear cell papillary renal cell carcinoma: Exploring SDHB protein immunohistochemistry and the relationship to tuberous sclerosis complex. *Hum Pathol* 2017, in press.
248. Dickson BC, Swanson D, Charames GS, Fletcher CDM, **Hornick JL**. Epithelioid fibrous histiocytoma: molecular characterization of *ALK* fusion partners in 23 cases. *Mod Pathol* 2017, in press.
249. Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahma M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desai IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, **Hornick JL**, Lobmaier I, Terrier P, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series. *JAMA Oncol* 2018, in press.

Jason L. Hornick, M.D., Ph.D.

250. Mito JK, Bishop JA, Sadow PM, Stelow EB, Faquin WC, Mills SE, Krane JF, French CA, Fletcher CDM, **Hornick JL**, Sholl LM, Jo VY. Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas. *Am J Surg Pathol* 2018, in press.
251. Yergulun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui J, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson M, Fuchs CS, Ogino S, **Hornick JL**, Hezel AR, Koong AC, Nowak JA, Wolpin BM. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. *Genet Med* 2018, in press.
252. Schaefer IM, Fletcher JA, Nielsen GP, Shih AR, Ferrone ML, **Hornick JL**, Qian X. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in limited biopsy samples. *Cancer Cytopathol* 2018, in press.

* Co-first or last authors.

Other peer-reviewed publications

1. George S, **Hornick JL**, Bertagnolli MM, Fletcher CDM, Demetri GD. Current management of metastatic gastrointestinal stromal tumor: A case report. *Clin Adv Hematol Oncol* 2003;1:63-64.
2. Bracht LK, Wen P, Meyerhardt JA, Kulke MH, **Hornick JL**, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. *J Clin Oncol* 2008;26:4843-4844.
3. Permaul P, Narla A, **Hornick JL**, Pai S-Y. Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: Case report and review of outcomes. *Immunol Res* 2009;44:89-98.
4. Long KB, Butrynski JE, Blank SD, Ebrahim KS, Dressel DM, Heinrich MC, Corless CL, **Hornick JL**. Primary extra-gastrointestinal stromal tumor of the pleura: Report of a unique case with genetic confirmation. *Am J Surg Pathol* 2010;34:907-912.
5. Elco CP, Mariño-Enríquez A, Abraham JA, Dal Cin P, **Hornick JL**. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: Report of a case providing further evidence for a pathogenetic link. *Am J Surg Pathol* 2010;34:1723-1727.
6. Liang C-W, Mariño-Enríquez A, Johannessen C, **Hornick JL**, Dal Cin P. Translocation (Y;12) in lipoma. *Cancer Genet* 2011;204:53-56.
7. Shinagare AB, Ramaiya NH, O'Regan K, Jagannathan JP, **Hornick JL**, LaCasce AS. *Helicobacter pylori* negative gastric MALT lymphoma. *J Clin Oncol* 2011;29:e297-300.

8. Saboo SS, Jagannathan JP, Krajewski KM, O'Regan K, **Hornick JL**, Fisher DC, Ramaiya N. Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation and surgery. *J Clin Oncol* 2011;29:e772-775.
9. Sneag D, Ramaiya N, O'Regan KN, Jagannathan JP, **Hornick JL**, Ho VT, Hayes JH. Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation. *Clin Genitourin Cancer* 2011;9:124-129.
10. Shinagare AB, Ramaiya NH, Jagannathan JP, **Hornick JL**, Swanson RS. Primary follicular dendritic cell sarcoma of liver treated with CHOP regimen and surgery. *J Clin Oncol* 2011;29:e849-851.
11. Hagen C, Lefferts J, **Hornick JL**, Srivastava A. "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to a germline *MSH2* mutation and somatic *MLH1* hypermethylation. *Am J Surg Pathol* 2011;35:1902-1905.
12. Jagannathan JP, Ramaiya NH, Shinagare AB, **Hornick JL**, George S. Intracranial metastasis from pediatric GI stromal tumor. *J Clin Oncol* 2012;30:e122-e125.
13. Javery O, Jagannathan JP, Saboo SS, O'Regan K, **Hornick JL**, Ramaiya NH. Atypical lipomatous tumor with unusual extensive metaplastic ossification. *Cancer Imaging* 2012;12:25-30.
14. Saboo SS, Krajewski KM, Shinagare AB, Jagannathan JP, **Hornick JL**, Ramaiya N. Imaging features of primary extranodal histiocytic sarcoma: Report of two cases and a review of the literature. *Cancer Imaging* 2013;12:253-258.
15. Bankova LG, Walter JE, Iyengar SR, Lorenzo ME, **Hornick JL**, Castells M. Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. *J Allergy Clin Immunol: In Practice* 2013;1:94-96.
16. Abi-Raad R, Manetti GJ, Colberg JW, **Hornick JL**, Shah JG, Prasad ML. Ewing sarcoma/primitive neuroectodermal tumor arising in the adrenal gland. *Pathol Int* 2013;63:283-286.
17. Eastham AB, **Hornick J**, Gaviola G, Vleugels RA. A 52-year-old woman with subcutaneous nodules and abdominal pain. *Clin Exp Dermatol* 2014;39:547-549.
18. Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, **Hornick JL**, George S. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. *Abdom Imaging* 2014;39:33-39.

19. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, George TL, Kluin-Nelemans HC, Hermine O, Butterfield JH, Hägglund H, Ustun C, **Hornick JL**, Triggiani M, Radia D, Akin C, Hartmann K, Gotlib J, Schwartz LB, Verstovsek S, Orfao A, Metcalfe DD, Arock M, Horny HP. Refined diagnostic criteria and classification of mast cell leukemia and myelomastocytic leukemia: A consensus proposal. *Ann Oncol* 2014;25:1691-1700.
20. Wong WJ, Lauria A, **Hornick JL**, Sheng Xiao S, Fletcher JA, Marino-Enriquez A. Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. *Genes Chromosomes Cancer* 2016;55:25-29.
21. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Nidoszytko M, Castells M, Oude Elberink JNG, Bonadonna P, Zanotti R, **Hornick JL**, Torrelo A, Grabbe J, Rabenhorst A, Nidoszytko B, Butterfield JH, Gotlib J, Reiter A, Radia D, Hermine O, Sotlar K, George TI, Kristensen TK, Kluin-Nelemans HC, Yavuz S, Hägglund H, Sperr WR, Schwartz LB, Triggiani M, Maurer M, Nilsson G, Horny HP, Arock M, Orfao A, Metcalfe DD, Akin C, Valent P. Cutaneous manifestations in mastocytosis: Consensus report of the European Competence Network on Mastocytosis (ECNM), AAAAI and EAACI. *J Allergy Clin Immunol* 2016;137:35-45.
22. Chiang AL, **Hornick JL**, Sahni VA, Clancy TE, Ryou M. Autoimmune pancreatitis presenting as multifocal masses, diagnosed on ampullary biopsy. *Pancreas*. 2016;45:e25-e27.
23. Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, **Hornick JL**, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine - part 1: Fit-for-purpose approach to classification of clinical immunohistochemistry biomarkers. *Appl Immunohistochem Mol Morphol* 2017;25:4-11.
24. Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, **Hornick JL**, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine - part 2: Immunohistochemistry test performance characteristics. *Appl Immunohistochem Mol Morphol* 2017;25:79-85.
25. Torlakovic EE, Cheung CC, D'Arrigo C, Dietel M, Francis GD, Gilks CB, Hall JA, **Hornick JL**, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Vyberg M, Zhou X, Taylor CR. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine - part 3: Technical validation of immunohistochemistry (IHC) assays in clinical IHC laboratories. *Appl Immunohistochem Mol Morphol* 2017;25:151-159.
26. Cheung CC, D'Arrigo C, Dietel M, Francis GD, Fulton R, Gilks CB, Hall JA, **Hornick JL**, Ibrahim M, Marchetti A, Miller K, van Krieken JH, Nielsen S, Swanson PE, Taylor CR, Vyberg M, Zhou X, Torlakovic EE. Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine - part 4: Tissue tools for quality assurance in immunohistochemistry. *Appl Immunohistochem Mol Morphol* 2017;25:227-230.

Reviews, chapters, monographs and editorials

1. Sharifi J, Khawli LA, **Hornick JL**, Epstein AL. Optimizing monoclonal antibody pharmacokinetics via chemical modification [review]. *Q J Nucl Med* 1998;42:242-249.
2. **Hornick JL**, Fletcher CDM. Validating immunohistochemical staining for KIT (CD117) [editorial]. *Am J Clin Pathol* 2003;119:325-327.
3. **Hornick JL**, Fletcher CDM. Criteria for malignancy in non-visceral smooth muscle tumors [review]. *Ann Diagn Pathol* 2003;7:60-66.
4. **Hornick JL**, Fletcher CDM. The significance of KIT (CD117) in gastrointestinal stromal tumors [review]. *Int J Surg Pathol* 2004;12:93-97.
5. **Hornick JL**, Fletcher CDM. PEComa: What do we know so far? [review] *Histopathology* 2006;48:75-82.
6. **Hornick JL**, Fletcher CDM. H&E will hold sway: The invaluable role of morphology in the molecular era. In: Hall PA, Wright NA, eds. *Understanding Disease: A Centenary Celebration of the Pathological Society*. Chichester, U.K.: John Wiley and Sons, 2006.
7. **Hornick JL**. Cellular neurothekeoma. In: Zembowicz A, Flotte TJ, Mihm MC, et al., eds. *Cases in Dermatopathology: Common Problems in Diagnosis of Pigmented Lesions*. Brisbane, Australia: Knowledge Books and Software, 2006.
8. Raut CP, **Hornick JL**, Bertagnolli MM. Advanced gastrointestinal stromal tumor: Potential benefits of aggressive surgery combined with targeted tyrosine kinase inhibitor therapy [review]. *Am J Hematol/Oncol* 2006;5:707-712.
9. **Hornick JL**, Fletcher CDM. The role of KIT in the management of patients with gastrointestinal stromal tumors [review]. *Hum Pathol* 2007;38:679-687.
10. **Hornick JL**, Odze RD. Neoplastic precursor lesions in Barrett's esophagus [review]. *Gastroenterol Clin North Am* 2007;36:775-796.
11. Gleason B, **Hornick JL**. Inflammatory myofibroblastic tumours: Where are we now? [review] *J Clin Pathol* 2008;61:428-437.
12. Gleason B, **Hornick JL**. Myoepithelial tumours of skin and soft tissue: An update [review]. *Diagn Histopathol* 2008;14:552-562.
13. Hollmann TJ, **Hornick JL**, Murphy GF. Urticaria pigmentosa. In: Hoang MP, ed. *Cases in Dermatopathology: Diagnostic Pitfalls in Dermatopathology*. Brisbane, Australia: Knowledge Books and Software, 2008.

Jason L. Hornick, M.D., Ph.D.

14. **Hornick JL**, Odze RD. Polyps of the large intestine. In: Odze RD, Goldblum J, eds. *Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas*. 2nd edition. Philadelphia: Saunders/Elsevier, 2009.
15. Raut CP, **Hornick JL**, Bertagnolli MM. Gastrointestinal stromal tumors of gastric origin. In: Wang T, Fox J, Giraud A, eds. *The Biology of Gastric Cancers*. New York: Springer, 2009.
16. George S, **Hornick JL**, Antman KH, Demetri GD. Sarcomas of soft tissue and bone and gastrointestinal stromal tumors (GISTs). In: Skarin AT, ed. *Atlas of Diagnostic Oncology*. 4th edition. Philadelphia: Elsevier, 2009.
17. Liegl B, **Hornick JL**, Lazar AJF. Contemporary pathology of gastrointestinal stromal tumors [review]. *Hematol Oncol Clin N Am* 2009;23:49-68, vii-viii.
18. Wick MR, **Hornick JL**. Immunohistology of soft tissue and osseous neoplasms. In: Dabbs DJ, ed. *Diagnostic Immunohistochemistry: Theranostic and Genomic Applications*. 3rd edition. Philadelphia: Saunders/Elsevier, 2010.
19. **Hornick JL**. Myofibroblastic tumors in children [review]. *Surg Pathol Clin* 2010;3:653-688.
20. Hollmann TJ, **Hornick JL**. INI1-deficient tumors: Diagnostic features and molecular genetics [review]. *Am J Surg Pathol* 2011;35:e47-63.
21. Marrari A, Wagner AJ, **Hornick JL**. Predictors of response to targeted therapies for gastrointestinal stromal tumors [review]. *Arch Pathol Lab Med* 2012;136:483-489.
22. McAuley G, Jaganathan J, O'Regan K, Krajewski K, **Hornick JL**, Butrynski J, Ramaiya N. Extraskeletal osteosarcoma: A spectrum of imaging findings [review]. *Am J Roentgenol* 2012;198:W31-37.
23. Bakri A, Shinagare AB, Krajewski KM, Howard SA, Jagannathan JP, **Hornick JL**, Ramaiya NH. Synovial sarcoma: Imaging features of common and uncommon primary sites, metastatic patterns and treatment response [review]. *Am J Roentgenol* 2012;199:W208-215.
24. Saboo SS, Krajewski KM, Zukotynski K, Howard SA, Jagannathan JP, **Hornick JL**, Ramaiya NH. Imaging features of primary and secondary adult rhabdomyosarcoma [review]. *Am J Roentgenol* 2012;199:W694-703.
25. Barletta JA, **Hornick JL**. Succinate dehydrogenase-deficient tumors: Diagnostic features and clinical implications [review]. *Adv Anat Pathol* 2012;19:193-203.
26. Kamran S, Shinagare A, Howard SA, **Hornick JL**, Ramaiya N. A-Z of malignant peripheral nerve sheath tumors [review]. *Cancer Imaging* 2012;12:475-483.
27. Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB, **Hornick JL**, Ramaiya NH. Cancers of unknown primary sites: What radiologists need to know and what oncologists want to know [review]. *Am J Roentgenol* 2013;200:484-492.

28. Sholl LM, **Hornick JL**. Diagnosis of primary and metastatic germ cell tumors using embryonic stem cell transcription factors. In: Hayat MA, ed. *Stem Cells and Cancer Stem Cells*, vol. 9. New York: Springer, 2013.
29. Kindblom LG, Mertens F, Coindre JM, **Hornick JL**, Meis JM. Sclerosing epithelioid fibrosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
30. Folpe AL, Mertens F, **Hornick JL**. Low-grade fibromyxoid sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
31. **Hornick JL**, Fletcher CDM, Mertens F. Pseudomyogenic haemangioendothelioma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
32. **Hornick JL**, Fletcher JA, Fletcher CDM. Perineurioma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
33. **Hornick JL**, Michal M. Hybrid nerve-sheath tumours. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
34. Fletcher CDM, Antonescu C, **Hornick JL**, Heim S. Myoepithelioma/myoepithelial carcinoma/mixed tumor. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
35. **Hornick JL**, Pan CC. PEComa. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: International Agency for Research on Cancer, 2013.
36. **Hornick JL**. Tumors of the small and large intestines (including anal canal). In: Fletcher CD, ed. *Diagnostic Histopathology of Tumors*. 4th edition. Philadelphia: Churchill Livingstone/Elsevier, 2013.
37. Doyle LA, **Hornick JL**. Mesenchymal tumors of the gastrointestinal tract other than GIST [review]. *Surg Pathol Clin* 2013;6:425-473.
38. Tirumani SH, Jagannathan JP, **Hornick JL**, Ramaiya NH. Resistance to treatment in gastrointestinal stromal tumors: What radiologists should know [review]. *Clin Radiol* 2013;68:e429-437.

Jason L. Hornick, M.D., Ph.D.

39. Doyle LA, **Hornick JL**. EWSR1 rearrangements in sclerosing epithelioid fibrosarcoma [letter]. *Am J Surg Pathol* 2013;37:1630-1631.
40. **Hornick JL**, ed. *Practical Soft Tissue Pathology: A Diagnostic Approach*. Philadelphia: Elsevier/Saunders, 2013.
41. Doyle LA, **Hornick JL**. Immunohistology of neoplasms of soft tissue and bone. In: Dabbs DJ, ed. *Diagnostic Immunohistochemistry: Theranostic and Genomic Applications*. 4th edition. Philadelphia: Saunders/Elsevier, 2014.
42. **Hornick JL**. Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors [review]. *Mod Pathol* 2014;27(S1):S47-S63.
43. **Hornick JL**, Mangham DC. Annual review issue: Soft tissue tumour pathology [editorial]. *Histopathology* 2014;64:1.
44. Doyle LA, **Hornick JL**. Gastrointestinal stromal tumors: From KIT to succinate dehydrogenase [review]. *Histopathology* 2014;64:53-67.
45. Doyle LA, **Hornick JL**. Pathology of extramedullary mastocytosis [review]. *Immunol Allergy Clin N Am* 2014;34:323-339.
46. **Hornick JL**, Odze RD. Polyps of the large intestine. In: Odze RD, Goldblum J, eds. *Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas*. 3rd edition. Philadelphia: Saunders/Elsevier, 2014.
47. Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith J, **Hornick JL**, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson P, Zhou X, Taylor CR, Vyberg M. Standardization of positive controls in diagnostic immunohistochemistry: Recommendations from the international *ad hoc* expert committee. *Appl Immunohistochem Mol Morphol* 2015;23:1-18.
48. Bellizzi AM, **Hornick JL**. The stomach. In: Wick MR, ed. *Silverberg's Principles and Practice of Surgical Pathology and Cytopathology*. 5th edition. Philadelphia: Churchill Livingstone/Elsevier, 2015.
49. **Hornick JL**, Brooks JSJ. Disorders of soft tissue. In: Mills SE, Greenson JK, **Hornick JL**, Longacre TA, Reuter VE, eds. *Sternberg's Diagnostic Surgical Pathology*. 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2015.
50. Conner JR, **Hornick JL**. Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry [review]. *Adv Anat Pathol* 2015;22:149-167.
51. Castells M, **Hornick JL**, Akin C. Anaphylaxis after Hymenoptera sting: Is it venom allergy, a clonal disorder or both? *J Allergy Clin Immunol Pract* 2015;3:350-255.
52. **Hornick JL**. Immunohistochemistry 2015: Protein correlates of molecular alterations and predictive testing [editorial]. *Semin Diagn Pathol* 2015;32:323-4.

53. Hameed M, Corless C, George S, **Hornick JL**, Kakar S, Lazar AJ, Tang L, For The Members Of The Cancer Biomarker Reporting Committee College Of American Pathologists. Template for reporting results of biomarker testing of specimens from patients with gastrointestinal stromal tumors. *Arch Pathol Lab Med* 2015;139:1271-5.
54. Wortman JR, Tirumani SH, Jagannathan JP, Rosenthal MH, Shinagare AB, **Hornick JL**, Baldini EH, Ramaiya NH. Radiation therapy for soft-tissue sarcomas: A primer for radiologists [review]. *Radiographics* 2016;36:554-72.
55. Jo VY, **Hornick JL**. *Neoplastic Mimics in Soft Tissue and Bone Pathology*. New York: Demos Medical, 2016.
56. Fletcher CD, Folpe AL, **Hornick JL**. Testis and paratesticular tissue: Mesenchymal tumours of the spermatic cord and testicular adnexae. In: Moch M, Humphrey P, Ulbright T, Reuter V, eds. *WHO Classification of Tumours of the Urinary System and Male Genital Organs*. Lyon: International Agency for Research on Cancer, 2016.
57. Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, **Hornick JL**, Baldini EH, George S, Ramaiya NK, Jagannathan JP. Role of imaging in management of desmoid-type fibromatosis: A primer for radiologists [review]. *Radiographics* 2016;36:767-82.
58. Nowak JA, **Hornick JL**. Molecular evaluation of colorectal adenocarcinoma: Current practice and emerging concepts [review]. *Surg Pathol Clin* 2016;9:427-39.
59. Kelil, T, Keraliya AR, Howard, SA, Krajewski, KM, Braschi-Amirfarzan M, **Hornick JL**, Ramaiya, NH, Tirumani, SH. Current concepts in molecular genetics and management of thyroid malignancies: An update for radiologists [review]. *Radiographics* 2016;36:1478-93.
60. Yoon SS, Maki RG, Asare EA, Cooper K, **Hornick JL**, Lazar A, Keedy VL, Kirsch DG, Madewell JE, Panicek DM, Randall RL, Tedder PS, Pollock RE. Soft tissue sarcoma of the trunk and extremities. In: Amin MB, Greene FL, Edge S, Schilsky RL, Gaspar LE, eds. *AJCC Cancer Staging Manual*. 8th Ed. New York: Springer, 2017; pp. 507-515.
61. Raut CP, Maki RG, Baldini EH, **Hornick JL**, Lazar A, Riedel RF, Tedder PS, Pollock RE. Soft tissue sarcoma of the abdomen and visceral organs. In: Amin MB, Greene FL, Edge S, Schilsky RL, Gaspar LE, eds. *AJCC Cancer Staging Manual*. 8th Ed. New York: Springer, 2017; pp. 517-521.
62. DeMatteo RP, Maki RG, Agulnik M, Brookland RK, **Hornick JL**, Jones RL, Keedy VL, Lazar A, O'Sullivan B, Raut CP, Tedder PS, Pollock RE. Gastrointestinal stromal tumor. In: Amin MB, Greene FL, Edge S, Schilsky RL, Gaspar LE, eds. *AJCC Cancer Staging Manual*. 8th Ed. New York: Springer, 2017; pp. 523-529.

63. Pollock RE, Maki RG, Baldini EH, **Hornick JL**, Keedy VL, Lazar A, Madewell JE, Raut CP, Tedder PS, Yoon SS. Soft tissue sarcoma of the retroperitoneum. In: Amin MB, Greene FL, Edge S, Schilsky RL, Gaspar LE, eds. *AJCC Cancer Staging Manual*. 8th Ed. New York: Springer, 2017; pp. 531-537.
64. Sholl LM, Barletta JA, **Hornick JL**. Radiation-associated neoplasia: Clinical, pathologic and genomic correlates [review]. *Histopathology* 2017;70:70-80.
65. Richman D, Tirumani SH, **Hornick JL**, Fuchs CS, Howard S, Krajewski K, Ramaiya N, Rosenthal M. Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms [review]. *Abdom Radiol* 2017;42:124-140.
66. Hung YP, **Hornick JL**. Epithelioid soft tissue tumors: A clinicopathologic and molecular update. *Am J Surg Pathol Rev Reports* 2017;22:62-74.
67. Schaefer IM, Cote GM, **Hornick JL**. Contemporary sarcoma diagnosis, genetics, and genomics. *J Clin Oncol* 2018;36:101-110.
68. Doyle LA, **Hornick JL**. Immunohistology of neoplasms of soft tissue and bone. In: Dabbs DJ, ed. *Diagnostic Immunohistochemistry: Theranostic and Genomic Applications*. 5th edition. Philadelphia: Saunders/Elsevier, 2018.
69. **Hornick JL**, ed. *Practical Soft Tissue Pathology: A Diagnostic Approach*, 2nd ed. Philadelphia: Elsevier/Saunders, 2018.
70. Andrici J, Gill AJ, **Hornick JL**. Next generation immunohistochemistry: Emerging substitutes to genetic testing? *Sem Diagn Pathol* 2018, in press.
71. **Hornick JL**, Laskin WB. Myxoinflammatory fibroblastic sarcoma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
72. Requena L, **Hornick JL**. Epithelioid fibrous histiocytoma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
73. Billings S, Brenn T, **Hornick JL**. Cutaneous angiosarcomas. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
74. **Hornick JL**, Billings S, Requena L. Haemangioendotheliomas. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
75. Requena L, **Hornick JL**, McCalmont TH. Cellular neurothekeoma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.

Jason L. Hornick, M.D., Ph.D.

76. Zelger B, **Hornick JL**. Perineurioma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
77. **Hornick JL**, Patel RM. Epithelioid sarcoma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
78. **Hornick JL**, Fisher C, LeBoit PE. Myoepithelioma. In: Elder D, Massi D, Scolyer R, Willemze R, eds. *WHO Classification of Skin Tumours*. Lyon: International Agency for Research on Cancer, 2018, in press.
79. Schaefer IM, **Hornick JL**, Bovée J. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: Genetics, pathology, and molecular mechanisms. *Lab Invest* 2018, in press.
80. Hung YP, **Hornick JL**. Immunohistochemical biomarkers of mesenchymal neoplasms in endocrine organs: Diagnostic pitfalls and recent discoveries. *Endocr Pathol* 2018, in press.

Thesis

Hornick JL. Engineering antibodies and antibody-cytokine fusion proteins for the treatment of human malignancies [dissertation]. Los Angeles (CA): University of Southern California; 1997.

Narrative report

I am the Director of Surgical Pathology and Director of the Immunohistochemistry Laboratory at the Brigham and Women's Hospital. Within the Department of Pathology, I am a member of the Education Committee, the Clinical Operations Committee, and the Resident Recruitment and Selection Committee. I co-chair the Tissue Committee at the Brigham and Women's Hospital. I am on the Executive Committee of the Mastocytosis Center and a member of the Cancer Committee at the Dana Farber/Brigham and Women's Cancer Center and the Steering Committees for the Center for Esophageal and Gastric Cancer, the Pancreaticobiliary Tumor Center, and the Center for Cancer Precision Medicine at the Dana Farber/Brigham and Women's Cancer Center.

My expertise and commitment to clinical innovation have been recognized by my contributions to major national and international organizations. I participated in the consensus and editorial working group for the 4th edition of the World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone and currently serve as an expert member of the editorial board for the 5th edition. I served as a member of the Soft Tissue Sarcoma Expert Panel for the American Joint Committee on Cancer (AJCC) Staging System and the Sarcoma Analysis Working Group of The Cancer Genome Atlas. I chaired the Immunohistochemistry Committee of the College of American Pathologists, leading the proficiency testing program that helps maintain quality for thousands of immunohistochemistry laboratories. I previously chaired the Abstract Review Board and Abstract Assignment Committee and currently chair the Education Committee of the United States and Canadian Academy of Pathology (USCAP), overseeing the academic and educational content of one of the largest pathology conferences in the world. I serve on the Councils of the Association of Directors of Anatomic and Surgical Pathology and the Arthur Purdy Stout Society of Surgical Pathologists, leading educational and practice improvement organizations in anatomic pathology. I also serve on the Test Development and Advisory Committee for Anatomic Pathology for the American Board of Pathology. I serve on the editorial boards of twelve journals, including *Modern Pathology* and the *American Journal of Surgical Pathology*, the leading journals in surgical pathology, and hold senior leadership positions on the editorial boards of *Histopathology* (Regional Editor for North America), *Advances in Anatomic Pathology* (Associate Editor), *Surgical Pathology Clinics* (Consulting Editor), and *Archives of Pathology and Laboratory Medicine* (Executive Advisory Board). I am an Associate Editor for *Sternberg's Diagnostic Surgical Pathology*, one of the most widely used reference textbooks in anatomic pathology. The focus of my clinical and translational research efforts is outlined below.

Soft tissue sarcomas are a rare and heterogeneous group of neoplasms with marked differences in metastatic potential and clinical course. Accurate diagnosis is critical for prognostication and appropriate patient management. However, given the rarity of sarcomas and their overlapping histologic appearances, surgical pathologists have great difficulty diagnosing these tumor types reproducibly. Over the past several decades, the molecular pathogenetic basis for many soft tissue tumors has been identified, including chromosomal translocations, deletions, amplifications, and mutations. In order to provide objective and more widely available methods for diagnosis, I have focused on the development of protein-based diagnostic biomarkers for soft tissue tumors that correlate with molecular genetic alterations, which can be evaluated by immunohistochemistry. Many of the markers we introduced have dramatically changed clinical practice and have become standard of care for confirming the histologic diagnosis of these rare tumor

types. Examples of these markers include INI1 (SMARCB1) for epithelioid sarcoma (Am J Surg Pathol 2009;33:542-550); MUC4 for low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma (Am J Surg Pathol 2011;35:733-741 and Am J Surg Pathol 2012;36:1444-1451); retinoblastoma for spindle cell/pleomorphic lipoma, mammary-type myofibroblastoma, and cellular angiofibroma (Am J Surg Pathol 2012;36:1119-1128); STAT6 for solitary fibrous tumor (Mod Pathol 2014;27:390-395); ALK for epithelioid fibrous histiocytoma (Mod Pathol 2015;28:904-12); ROS1 for inflammatory myofibroblastic tumor (Mod Pathol 2015;28:732-739); CAMTA1 for epithelioid hemangioendothelioma (Am J Surg Pathol 2016;40:94-102); H3K27me3 (histone H3 with lysine 27 trimethylation) for malignant peripheral nerve sheath tumor (Mod Pathol 2016;29:4-13); ETV4 for sarcomas with *CIC* rearrangements (Mod Pathol 2016;29:1324-1334); and FOSB for pseudomyogenic hemangioendothelioma and epithelioid hemangioma (Am J Surg Pathol 2017;41:596-606).

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Most GISTs are driven by mutations in (and constitutive activation of) the receptor tyrosine kinase gene *KIT*, or, less often, *PDGFRA*; tyrosine kinase inhibitor therapies are effective treatments for many patients with advanced GIST. Around 10% of GISTs (often referred to as “wild-type” GISTs) lack such mutations and do not respond to these targeted therapies. I have investigated the pathogenesis of this subset of GISTs and have recognized that the majority of such tumors have distinctive clinical and pathologic features; moreover, these tumors can be identified based on their histologic appearances (Am J Surg Pathol 2011;35:495-504). These tumors are driven by mutations in the succinate dehydrogenase (SDH) complex subunit genes and have therefore become known as “SDH-deficient GISTs”; the diagnosis can be confirmed by immunohistochemistry (loss of expression of SDHB is limited to SDH-deficient GISTs; Histopathology 2012;61:801-809). We demonstrated that SDH-deficient GISTs are associated with decreased production of 5-hydroxymethylcytosine, implicating global hypermethylation in the development of these tumors (Mod Pathol 2013;26:1492-1497). We also showed that loss of SDHA protein expression specifically identifies tumors with *SDHA* mutations (Mod Pathol 2013;26:289-294) and that conventional risk stratification criteria do not predict progression of SDH-deficient GISTs (Am J Surg Pathol 2016;40:1616-1621). These studies have changed surgical pathology practice such that SDH-deficient GISTs can be diagnosed more reproducibly.

Another major focus of my research is defining diagnostic criteria for soft tissue tumors and identifying features associated with malignancy and aggressive behavior. For example, we first identified hybrid schwannoma/perineurioma, a distinctive benign nerve sheath tumor unassociated with neurofibromatosis or other neurocristopathies (Am J Surg Pathol 2009;33:1554-1561); we demonstrated that dedifferentiated liposarcomas could show “homologous” lipoblastic differentiation in the higher grade component, resembling pleomorphic liposarcoma (Am J Surg Pathol 2010;34:1122-1131); and we reported an aggressive epithelioid variant of inflammatory myofibroblastic tumor with distinctive histology, a unique pattern of ALK expression, and a characteristic gene fusion (Am J Surg Pathol 2011;35:135-144). In recognition of my significant contributions to clinical innovation in surgical pathology, I received the 2012 Arthur Purdy Stout Society of Surgical Pathologists Annual Prize and the 2014 Jack Yardley Investigator Award from the Gastrointestinal Pathology Society.

Jason L. Hornick, M.D., Ph.D.

In terms of pathology education, I am dedicated to teaching residents, fellows, and practicing pathologists diagnostic approaches to soft tissue tumors, gastrointestinal pathology, and applications of diagnostic immunohistochemistry. I am co-director of the Surgical Pathology Update course at Brigham and Women's Hospital, co-director of the Diagnostic Pathology Update course for the USCAP, and director of the Interactive Microscopy Soft Tissue Pathology course for USCAP. I was previously moderator of the Bone and Soft Tissue Pathology specialty conference at the USCAP annual meeting. I regularly lecture in Harvard continuing medical education courses and have delivered more than 100 invited lectures for departmental grand rounds and national and international conferences. I routinely participate in symposia at International Academy of Pathology congresses and the European Congress of Pathology, and I have taught three consecutive three-year short courses at the USCAP annual meetings. I am the Editor of the textbook *Practical Soft Tissue Pathology*, which serves as a guide to the diagnosis of mesenchymal neoplasms for pathology residents, fellows, and practicing pathologists; the 2nd edition of this textbook was recently published.

In summary, I am dedicated to the advancement of diagnostic surgical pathology through improving tumor classification, defining histologic parameters that predict outcome, translating discoveries in basic biomedical research to clinical practice, and teaching approaches to diagnostic pathology to trainees and practitioners. I look forward to continuing to train future academic and practicing surgical pathologists.